

Curriculum vitae

Umberto Malapelle, Ph.D.

Professore Associato in Anatomia Pathologica,
Dipartimento di Sanità Pubblica,
Università degli Studi di Napoli “Federico II”,
via S. Pansini 5, 80131, Napoli, Italia

Informazioni generali:

Data e luogo di nascita: 17/04/1985; Napoli.

Indirizzo lavorativo: Dipartimento di Sanità Pubblica, Università degli Studi di Napoli “Federico II”, via S. Pansini 5, 80131, Napoli, Italia.

Cell: + 39 3203850702.

E- mail: umberto.malapelle@unina.it

Lingue: Italiano (lingua madre)

Inglese (Buona capacità di scrittura, lettura e dialogo)

Spagnolo (Buona capacità di scrittura, lettura e dialogo)

Titolo di studio

2009: Laurea Magistrale in Biotecnologie Mediche, summa cum laude, Università degli Studi di Napoli “Federico II”, Napoli, Italia.

2013: Ph.D. in Anatomia Patologica, “Titolo della tesi: “Valutazione dello stato mutazionale degli oncogeni predittivi di risposta terapeutica al trattamento di EGFR: validazione analitica e clinica.”, Università degli Studi di Napoli “Federico II”, Napoli, Italia.

Abilitazione all'esercizio della professione di biologo:

AA_074980, Napoli. (dal 24/02/2016)

Abilitazione Scientifica Nazionale a Professore di II Fascia dal 29/04/2019 sl 29/04/2025 (art. 16, comma 1, legge 240/10)

Membro della Commissione Scientifica, Scuola di Medicina Member of the Scientific Commission, School of medicine, Università degli Studi di Napoli “Federico II”. (D.R. n. 3422 of 26/10/2020)

**Membro del “Tavolo Tecnico sulla Medicina di Precisione e Prescrittomica”, AIFA,
Determina Presidenziale 621/20.**

Esperienze professionali

2008: Research Partnership Italia-Spain. Laboratorio di Patologia Molecolare (Prof. M. A. Piris) Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spagna.

2010: Corso di formazione in “Laser capture microdissection with PALM MicroBeamsystem (Zeiss), Unità di Diagnostica Molecolare (Prof. Luis Lombardia), Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spagna.

2013: Corso di formazione Ion PGM Training presso Life Technologies in Frankfurter Str. 129B, 64293 Darmstadt, Germania.

2015 - 2017 Research Partnership Laboratorio di Patologia Molecolare Predittiva, Pangaea Inst/Dexeus University, Barcellona, Spagna.

Progetti di Ricerca Nazionali ed Internazionali

- 2008-2010: Membro del gruppo di ricerca, Italia-Spagna Partnership (MIUR grant, IT1816). Role of akt kinase in growth control of haematological and solid neoplasms. In collaborazione con Dr. Miguel Angel Piris del Programa de Patologia Molecular Centro Nacional de Investigaciones Oncologicas, Madrid, Spagna.
- 2009-2012: Membro del progetto PRIN: Histological and immunohistochemical effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats, Università degli Studi di Napoli “Federico II”, Napoli, Italia.
- 2015-oggi: Co-Investigatore del Progetto di Ricerca “Molecular Biology in indeterminate thyroid FNA” finanziato da Regione Campania (Legge Regionale n. 24 del 29/12/2005).
- 2016-present: Co-Investigatore del Progetto di Ricerca “Traslation in clinical practice of ctDNA analysis for EGFR mutation in NSCLC patients” Promotore: Università degli Studi di Napoli “Federico II”, Napoli, Italia.

Incarichi Accademici:

- 2013 - oggi: Relatore al Master teorico-pratico di I livello in “Metodologie di Anatomia Patologica per lo studio dei biomarcatori predittivi di risposta terapeutica” (coordinatore prof. Giancarlo Troncone), Dipartimento di Sanità Pubblica, Università degli Studi di Napoli “Federico II”, Napoli, Italia.

- 2016 – oggi: Docente in Anatomia Patologica, Scuola di Medicina e Chirurgia, • Università degli Studi di Napoli “Federico II”, Napoli, Italia.
- 2016 – oggi: Docente in Anatomia Patologica, Corso di Laurea in Tecniche Neurofisiopatologiche, Università degli Studi di Napoli “Federico II”, Napoli, Italia.
- 2016 – oggi: Docente in Anatomia Patologica, Corso di Laurea per Tecnici audiometrici, Università degli Studi di Napoli “Federico II”, Napoli, Italia.
- 2016 – oggi: Docente nella Scuola di Specializzazione in Anatomia Patologica, Università degli Studi di Napoli “Federico II”, Napoli, Italia.
- 2019-oggi: Chair of Young Investigators dell’International Society of Liquid Biopsy.
- 2020-presente: Membro del pannello dei revisori per student di dottorato, Università degli Studi di Bologna, Bologna, Italia.
- 2020 – presente: Membro del "NETWORK ONCOLOGY AND PRECISION MEDICINE" Ph.D. Program, Università "La Sapienza", Roma, Italia.
- 2021 – presente: Membro della Breast Unit, Università degli Studi di Napoli “Federico II”, Napoli, Italia.
- 2021 – presente: Supervisore per l’ International PhD Course in Molecular Medicine, Curriculum in Experimental and clinical medicine, Università San Raffaele, Milano, Italia.
- 2021 – presente: Supervisore per Doctoral School in Life and Health Sciences PhD Program in Complex System for Life Sciences, Università di Torino, Italia.
- 2021: UICC Virtual Fellowship. 18 maggio 2021. Clinical and Translational Research in Lung Cancer.
- 2021-presente: Segretario della International Society of Liquid Biopsy.
- 2023-presente: Membro della ESMO Communication Committee.
- 2023-presente: Membro dell’External Scientific Committee dell’ Instituto Valenciano de Oncologia (FIVO).
- 2024-present: Membro della “Commissione paritetica docenti/allievi dottorali della Scuola Superiore Meridionale di Area Scientifico – Tecnologica” (delibera del Comitato Ordinatore della Scuola Superiore Meridionale, n.14 del 29/01/2024).
- 2024-presente ESMO TAT - faculty - invited speaker
- 2024: Internship Supervisor per il modulo Internship/project dell’European MSc in Molecular Pathology durante l’anno accademico 2023-2024.

Incarichi Editoriali:

- 2020-oggi: Associate Editor di Frontiers in Oncology per la sezione “Thoracic Oncology”.
- 2020-oggi: Associate Editor di Frontiers in Oncology per la sezione “Women’s Cancer”.
- 2020-oggi: Deputy Editor di Critical Reviews in Oncology/Hematology.
- 2020-oggi: Membro dell’Editorial Board di Journal of Molecular Pathology.
- 2020-oggi: Membro dell’Editorial Board di Cells.
- 2023-oggi: Editor in Chief of The Journal of Liquid Biopsy.
- 2024-oggi: Membro dell’Editorial Board di Molecular Diagnosis & Therapy.
-

Attività di trasferimento tecnologico

- 2017 – oggi: Membro proponente della Spin – Off del Dipartimento di Sanità Pubblica, Università degli Studi di Napoli “Federico II”, GENEDIN s.r.l. (Via Giovanni Devoti 14, 00167, Roma, Italia).
- Ideatore e proprietario (50%) del pannello SiRe® (CE – IVD), un pool di oligonucleotidi per la caratterizzazione dell’assetto molecolare di geni predittivi di risposta al trattamento con terapie farmacologiche mirate nel carcinoma del colon-retto metastatico, carcinoma del polmone a cellule non piccole, melanoma e tumori gastrointestinali stromali.

Reviewer Per Progetti Internazionali

- partecipante come reviewer ai progetti della Dutch Cancer Society (KWF).

Expertise and contributo alla patologia molecolare predittiva:

Mi sono laureato in biotecnologie mediche presso l’Università degli Studi di Napoli “Federico II” nel 2009, quindi mi sono formato presso il Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spagna nell’ambito della Research Partnership con il gruppo diretto dal Prof. M. A. Pirirs. Ho conseguito il titolo di dottore di ricerca in Anatomia Patologica presso l’Università degli Studi di Napoli “Federico II”, nel 2013 (Coordinatore Prof.ssa Stefania Montagnani), quindi ho collaborato con il Pangaea Inst/Dexeus University, Barcellona, Spagna nel 2016 sotto la supervisione del Prof. R. Rosell. Dal 2015 sono Ricercatore presso l’Università degli Studi di Napoli “Federico II”.

Dal 2008 al 2010 ho fatto parte come membro del gruppo di ricerca Italia-Spagna (MIUR grant, IT1816). Role of akt kinase in growth control of hematological and solid neoplasms. In collaborazione con il Dr. Miguel Angel Piris del Programa de Patologia Molecular Centro Nacional de Investigaciones Oncologicas Madrid, Spagna.

Dal 2009 al 2012 ho preso parte al progetto PRIN: Histological and immunohistochemical effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.

Dal 2015 ad oggi sono Co-Investigatore del progetto di ricerca “Molecular Biology in indeterminate thyroid FNA” finanziato dalla Regione Campania (L.R. n. 24 del 29/12/2005).

Dal 2016 ad oggi sono Co-Investigatore del progetto di ricerca “Traslation in clinical practice of ctDNA analysis for EGFR mutation in NSCLC patients” promosso dall’Università degli Studi di Napoli Federico II.

Sono expert member dell’International Society of Liquid Biopsy (ISLB) e membro del board del Gruppo Italiano di Patologia Molecolare e Medicina Predittiva (PMMP).

Attualmente sono Chief Supervisor del laboratorio di Patologia Molecolare Predittiva presso il Dipartimento di Sanità Pubblica dell’Università degli Studi di Napoli “Federico II”. Il mio ambito di ricerca è focalizzato sull’oncologia molecolare e sull’immunoterapia nelle neoplasie del distretto toracico ed in generale per i tumori solidi, adottando tecnologie di nuova generazione sia su campioni tissutali sia su campioni di biopsia liquida, in particolare su DNA tumorale circolante.

Ho sviluppato il pannello NGS Sire® per l’identificazione di mutazioni clinicamente rilevanti nei NSCLC, GIST, mCRC e melanomi metastatici. Sono tra i fondatori della Spin – off universitaria Genedin.

Membro delle linee guida italiane

2019 - presente: AIOM – neoplasie polmonari;

2020 - presente: SIAPEC - Melanoma;

2020 - presente: AIOM, SIAPEC, SIF, SIBICO – patologia molecolare predittiva nei pazienti affetti da neoplasie solide

2022 - presente: AIOM, SIAPEC, SIF, SIBICO – Tumori Eredo-Familiari

Membro delle linee guida internazionali

2019 - presente: International Association for the Study of Lung Cancer (IASLC) – biopsia liquida nel carcinoma polmonare

Riconoscimenti

- Heroes of Pathology. The Power List 2024. The Pathologist. <https://thepathologist.com/power-list/2024/heroes-of-pathology/umberto-malapelle>

Papers:

1. Troncone G, Russo M, **Malapelle U**, Accardo M, Ferraro A, Cozzolino I, Palombini L. Cytological and molecular diagnosis of solid variant of papillary thyroid carcinoma: a case report. Cytojournal. 2008 Mar 19;5:2. doi: 10.1186/1742-6413-5-2. PMID: 18353179; PMCID: PMC2278161.
2. Troncone G, Cozzolino I, Fedele M, **Malapelle U**, Palombini L. Preparation of thyroid FNA material for routine cytology and BRAF testing: a validation study. Diagn Cytopathol. 2010 Mar;38(3):172-6. doi: 10.1002/dc.21166. PMID: 19693938.
3. Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, **Malapelle U**, Palmieri EA, Conzo G, Papotti M, Palombini L. Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. Cancer. 2009 Dec 25;117(6):522-9. doi: 10.1002/ency.20050. PMID: 19787802.
4. Troncone G, **Malapelle U**, Cozzolino I, Palombini L. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol. 2010 Dec;38(12):869-73. doi: 10.1002/dc.21302. PMID: 20049979.
5. Cozzolino I, **Malapelle U**, Carlomagno C, Palombini L, Troncone G. Metastasis of colon cancer to the thyroid gland: a case diagnosed on fine-needle aspirate by a combined cytological, immunocytochemical, and molecular approach. Diagn Cytopathol. 2010 Dec;38(12):932-5. doi: 10.1002/dc.21346. PMID: 20213843.
6. **Malapelle U**, Bellevicine C, Russo A, Salatiello M, Palombini L, Troncone G. KRAS testing on colo-rectal carcinoma cytological imprints. Diagn Cytopathol. 2011 Apr;39(4):274-7. doi: 10.1002/dc.21417. PMID: 20607679.
7. **Malapelle U**, Bellevicine C, Zeppa P, Palombini L, Troncone G. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol. 2011 Sep;39(9):703-10. doi: 10.1002/dc.21512. Epub 2010 Nov 9. PMID: 21837660.
8. **Malapelle U**, de Rosa N, Rocco D, Bellevicine C, Crispino C, Illiano A, Piantedosi FV, Nappi O, Troncone G. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot

study. *J Clin Pathol*. 2012 Jan;65(1):87-91. doi: 10.1136/jclinpath-2011-200296. Epub 2011 Sep 22. PMID: 21945923.

9. Bellevicine C, **Malapelle U**, Docimo G, Ciancia G, Mossetti G, Pettinato G, Troncone G. Multicentric encapsulated papillary oncocytic neoplasm of the thyroid: A case diagnosed by a combined cytological, histological, immunohistochemical, and molecular approach. *Diagn Cytopathol*. 2012 Maggio;40(5):450-4. doi: 10.1002/dc.21828. Epub 2011 Sep 30. PMID: 21965084.

10. Forzati F, Federico A, Pallante P, Abbate A, Esposito F, **Malapelle U**, Sepe R, Palma G, Troncone G, Scarfò M, Arra C, Fedele M, Fusco A. CBX7 is a tumor suppressor in mice and humans. *J Clin Invest*. 2012 Feb;122(2):612-23. doi: 10.1172/JCI58620. Epub 2012 Jan 3. Erratum in: *J Clin Invest*. 2013 Feb 1;123(2):934. PMID: 22214847; PMCID: PMC3266782.

11. **Malapelle U**, de Rosa N, Bellevicine C, Rocco D, Vitiello F, Piantedosi FV, Illiano A, Nappi O, Troncone G. EGFR mutations detection on liquid-based cytology: is microscopy still necessary? *J Clin Pathol*. 2012 Jun;65(6):561-4. doi: 10.1136/jclinpath-2011-200659. Epub 2012 Apr 1. PMID: 22466414.

12. Zeppa P, Sosa Fernandez LV, Cozzolino I, Ronga V, Genesio R, Salatiello M, Picardi M, **Malapelle U**, Troncone G, Vigliar E. Immunoglobulin heavy-chain fluorescence in situ hybridization-chromogenic in situ hybridization DNA probe split signal in the clonality assessment of lymphoproliferative processes on cytological samples. *Cancer Cytopathol*. 2012 Dec 25;120(6):390-400. doi: 10.1002/cncy.21203. Epub 2012 Apr 19. PMID: 22517675.

13. **Malapelle U**, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, Marciano R, Cimminiello C, Bellevicine C, De Placido S, Troncone G. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. *Br J Cancer*. 2012 Aug 7;107(4):626-31. doi: 10.1038/bjc.2012.275. Epub 2012 Jul 17. PMID: 22805329; PMCID: PMC3419946.

14. **Malapelle U**, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, Sparano L, De Stefano A, Carlomagno C, Maiello FM, Vita G, Nappi O, Troncone G. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. *J Clin Pathol*. 2012 Oct;65(10):940-4. doi: 10.1136/jclinpath-2012-200773. Epub 2012 Aug 7. PMID: 22872705; PMCID: PMC3461636.

15. Bellevicine C, **Malapelle U**, Iaccarino A, Schettino P, Napolitano V, Zeppa P, Troncone G. Foamy gland pancreatic ductal adenocarcinoma diagnosed on EUS-FNA: a histochemical, immunohistochemical, and molecular report. *Diagn Cytopathol*. 2013 Jan;41(1):77-80. doi: 10.1002/dc.22923. Epub 2012 Sep 25. PMID: 23008087.

16. Bellevicine C, Cozzolino I, **Malapelle U**, Zeppa P, Troncone G. Cytological and molecular features of papillary thyroid carcinoma with prominent hobnail features: a case report. *Acta Cytol.* 2012;56(5):560-4. doi: 10.1159/000338395. Epub 2012 Sep 27. PMID: 23075900.
17. Pallante P, **Malapelle U**, Berlingieri MT, Bellevicine C, Sepe R, Federico A, Rocco D, Galgani M, Chiariotti L, Sanchez-Cespedes M, Fusco A, Troncone G. UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. *Eur J Cancer.* 2013 Mar;49(5):1117-26. doi: 10.1016/j.ejca.2012.09.033. Epub 2012 Oct 24. PMID: 23102841.
18. Rosa R, Marciano R, **Malapelle U**, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. *Clin Cancer Res.* 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19. PMID: 23166225.
19. Bellevicine C, Zabatta A, **Malapelle U**, Vetrani A, Troncone G. Diffuse large B-cell extranodal lymphoma of the uterine cervix: an incidental pap smear finding with histological and immunohistochemical correlation. *Diagn Cytopathol.* 2014 Jul;42(7):644-6. doi: 10.1002/dc.22966. Epub 2013 Feb 26. PMID: 23441015.
20. Bellevicine C, Iaccarino A, **Malapelle U**, Troncone G. Warthin tumor with signet-ring cell features as a pitfall in salivary gland cytopathology. *Acta Cytol.* 2013;57(3):309-12. doi: 10.1159/000348248. Epub 2013 Apr 25. PMID: 23635480.
21. **Malapelle U**, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. *Cancer Cytopathol.* 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18. PMID: 23780873.
22. **Malapelle U**, Russo S, Pepe F, Sgariglia R, De Luca C, Bellevicine C, Pallante P, Troncone G. EGFR mutation detection by microfluidic technology: a validation study. *J Clin Pathol.* 2013 Nov;66(11):982-4. doi: 10.1136/jclinpath-2013-201730. Epub 2013 Jun 21. PMID: 23794480.
23. Bellevicine C, Iaccarino A, **Malapelle U**, Sasso FC, Biondi B, Troncone G. PAX8 is expressed in anaplastic thyroid carcinoma diagnosed by fine-needle aspiration: a study of three cases with histological correlates. *Eur J Endocrinol.* 2013 Jul 29;169(3):307-11. doi: 10.1530/EJE-13-0150. PMID: 23811186.
24. **Malapelle U**, Carlomagno C, de Luca C, Bellevicine C, Troncone G. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. *J Clin*

Pathol. 2014 Jan;67(1):1-9. doi: 10.1136/jclinpath-2013-201835. Epub 2013 Sep 10. PMID: 24022727.

25. Bellevicine C, Vita GD, **Malapelle U**, Troncone G. Applications and limitations of oncogene mutation testing in clinical cytopathology. Semin Diagn Pathol. 2013 Nov;30(4):284-97. doi: 10.1053/j.semdp.2013.11.008. Epub 2013 Nov 12. PMID: 24342285.

26. de Biase D, Visani M, **Malapelle U**, Simonato F, Cesari V, Bellevicine C, Pession A, Troncone G, Fassina A, Tallini G. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). PLoS One. 2013 Dec 23;8(12):e83607. doi: 10.1371/journal.pone.0083607. PMID: 24376723; PMCID: PMC3871524.

27. Bellevicine C, **Malapelle U**, de Luca C, Iaccarino A, Troncone G. EGFR analysis: current evidence and future directions. Diagn Cytopathol. 2014 Nov;42(11):984-92. doi: 10.1002/dc.23142. Epub 2014 Mar 12. PMID: 24619906.

28. Bellevicine C, Bianco A, **Malapelle U**, De Luca C, Vigliar E, Cacciola NA, Pallante P, Troncone G. Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study. Cytopathology. 2015 Apr;26(2):99-105. doi: 10.1111/cyt.12155. Epub 2014 Maggio 15. PMID: 24831172.

29. Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, **Malapelle U**, Troncone G, De Stefano A, Pepe S, De Placido S, D'Incalci M, Marzoini S, Carlomagno C. Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. Biomed Res Int. 2014;2014:840921. doi: 10.1155/2014/840921. Epub 2014 Jul 10. PMID: 25143946; PMCID: PMC4128171.

30. Vigliar E, **Malapelle U**, Bellevicine C, de Luca C, Troncone G. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice? Cytopathology. 2015 Oct;26(5):312-7. doi: 10.1111/cyt.12221. Epub 2014 Nov 7. PMID: 25376259.

31. **Malapelle U**, Vigliar E, Sgariglia R, Bellevicine C, Colarossi L, Vitale D, Pallante P, Troncone G. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. J Clin Pathol. 2015 Jan;68(1):64-8. doi: 10.1136/jclinpath-2014-202691. Epub 2014 Nov 5. PMID: 25378536.

32. Bellevicine C, **Malapelle U**, Vigliar E, de Luca C, Troncone G. Epidermal growth factor receptor test performed on liquid-based cytology lung samples: experience of an academic referral center. Acta Cytol. 2014;58(6):589-94. doi: 10.1159/000369756. Epub 2014 Nov 22. PMID: 25428205.

33. **Malapelle U**, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, Troncone G. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. *J Clin Pathol*. 2015 Apr;68(4):265-9. doi: 10.1136/jclinpath-2014-202761. Epub 2015 Jan 21. PMID: 25609577.
34. Bellevicine C, Vigliar E, **Malapelle U**, Pisapia P, Conzo G, Biondi B, Vetrani A, Troncone G. Cytopathologists can reliably perform ultrasound-guided thyroid fine needle aspiration: a 1-year audit on 3715 consecutive cases. *Cytopathology*. 2016 Apr;27(2):115-21. doi: 10.1111/cyt.12243. Epub 2015 Mar 21. PMID: 25810099.
35. Bellevicine C, Vigliar E, **Malapelle U**, Carelli E, Fiorelli A, Vicidomini G, Cappabianca S, Santini M, Troncone G. Lung adenocarcinoma and its thyroid metastasis characterized on fine-needle aspirates by cytomorphology, immunocytochemistry, and next-generation sequencing. *Diagn Cytopathol*. 2015 Jul;43(7):585-9. doi: 10.1002/dc.23264. Epub 2015 Apr 21. PMID: 25900221.
36. Cacciola NA, Calabrese C, **Malapelle U**, Pellino G, De Stefano A, Sepe R, Sgariglia R, Quintavalle C, Federico A, Bianco A, Uchimura Bastos A, Milone M, Bellevicine C, Milone F, Carlomagno C, Selvaggi F, Troncone G, Fusco A, Pallante P. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. *Mol Carcinog*. 2016 Maggio;55(5):793-807. doi: 10.1002/mc.22322. Epub 2015 Apr 27. PMID: 25917796.
37. **Malapelle U**, Vatrano S, Russo S, Bellevicine C, de Luca C, Sgariglia R, Rocco D, de Pietro L, Riccardi F, Gobbin E, Righi L, Troncone G. EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. *J Clin Pathol*. 2015 Sep;68(9):739-41. doi: 10.1136/jclinpath-2015-203101. Epub 2015 Jun 5. PMID: 26047622.
38. Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, **Malapelle U**, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. *Clin Cancer Res*. 2015 Oct 15;21(20):4686-97. doi: 10.1158/1078-0432.CCR-14-3319. Epub 2015 Jun 29. PMID: 26124204.
39. **Malapelle U**, De Stefano A, Carlomagno C, Bellevicine C, Troncone G. Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Li et al (2015). *J Clin Pathol*. 2015 Nov;68(11):946-7. doi: 10.1136/jclinpath-2015-203205. Epub 2015 Jul 2. PMID: 26139632.

40. Lucci R, Vigliar E, **Malapelle U**, Cigliano B, Troncone G, Bellevicine C. Fine-needle aspiration findings in focal (nodular) myositis of a newborn: A case report. *Diagn Cytopathol*. 2015 Nov;43(11):920-3. doi: 10.1002/dc.23309. Epub 2015 Jul 14. PMID: 26173198.
41. Vigliar E, **Malapelle U**, Troncone G. Cytopathology meets basic science. *Cancer Cytopathol*. 2015 Oct;123(10):571-2. doi: 10.1002/cncy.21578. Epub 2015 Jul 20. PMID: 26194340.
42. Cacciola NA, Sepe R, Forzati F, Federico A, Pellecchia S, **Malapelle U**, De Stefano A, Rocco D, Fusco A, Pallante P. Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. *Naunyn Schmiedebergs Arch Pharmacol*. 2015 Nov;388(11):1179-86. doi: 10.1007/s00210-015-1153-y. Epub 2015 Jul 28. PMID: 26216446.
43. Vigliar E, **Malapelle U**, de Luca C, Bellevicine C, Troncone G. Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective. *Cytopathology*. 2015 Oct;26(5):271-83. doi: 10.1111/cyt.12265. PMID: 26399861.
44. Pellino G, Pallante P, **Malapelle U**, Ferraro A, Bellevicine C, Milone M, Troncone G, Fusco A, Selvaggi F; INSIGH-T-R Collaborative. UbcH10 overexpression is less pronounced in older colorectal cancer patients. *Int J Colorectal Dis*. 2016 Jul;31(7):1367-8. doi: 10.1007/s00384-015-2481-6. Epub 2016 Jan 7. PMID: 26744065.
45. **Malapelle U**, Pisapia P, Sgariglia R, Vigliar E, Biglietto M, Carlomagno C, Giuffrè G, Bellevicine C, Troncone G. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. *J Clin Pathol*. 2016 Sep;69(9):767-71. doi: 10.1136/jclinpath-2015-203403. Epub 2016 Jan 21. PMID: 26797410; PMCID: PMC5036215.
46. **Malapelle U**, de Luca C, Vigliar E, Ambrosio F, Rocco D, Pisapia P, Bellevicine C, Troncone G. EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: a validation study. *J Clin Pathol*. 2016 Maggio;69(5):454-7. doi: 10.1136/jclinpath-2015-203429. Epub 2016 Feb 18. PMID: 26893402.
47. de Biase D, de Luca C, Gragnano G, Visani M, Bellevicine C, **Malapelle U**, Tallini G, Troncone G. Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. *J Clin Pathol*. 2016 Apr 27;jclinpath-2016-203696. doi: 10.1136/jclinpath-2016-203696. Epub ahead of print. PMID: 27122185.
48. **Malapelle U**, Morra F, Ilardi G, Visconti R, Merolla F, Cerrato A, Napolitano V, Monaco R, Guggino G, Monaco G, Staibano S, Troncone G, Celetti A. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. *Lung Cancer*. 2017 Maggio;107:41-49. doi: 10.1016/j.lungcan.2016.06.015. Epub 2016 Jun 17. PMID: 27372520.
49. De Luca C, Gragnano G, Pisapia P, Vigliar E, **Malapelle U**, Bellevicine C, Troncone G. EGFR mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based

Idylla EGFR Mutation Assay. *J Clin Pathol*. 2017 Apr;70(4):295-300. doi: 10.1136/jclinpath-2016-203989. Epub 2016 Aug 19. PMID: 27543600.

50. Bellevicine C, Sgariglia R, **Malapelle U**, Vigliar E, Nacchio M, Ciancia G, Eszlinger M, Paschke R, Troncone G. Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples? *Cancer Cytopathol*. 2016 Nov;124(11):776-784. doi: 10.1002/cncy.21780. Epub 2016 Sep 26. PMID: 27717198.

51. **Malapelle U**, Pisapia P, Rocco D, Smeraglio R, di Spirito M, Bellevicine C, Troncone G. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. *Transl Lung Cancer Res*. 2016 Oct;5(5):505-510. doi: 10.21037/tlcr.2016.10.08. PMID: 27826531; PMCID: PMC5099511.

52. Pepe F, Smeraglio R, Vacirca D, **Malapelle U**, Barberis M, Troncone G. Microsatellite instability evaluation by automated microfluidic electrophoresis: an update. *J Clin Pathol*. 2017 Jan;70(1):90-91. doi: 10.1136/jclinpath-2016-204200. Epub 2016 Nov 21. PMID: 27872139.

53. Cortinovis D, Gregorc V, Migliorino MR, Abate MI, Manzo A, **Malapelle U**, Morabito A; Italian Lung Cancer Working Group. New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. *Crit Rev Oncol Hematol*. 2017 Jan;109:35-41. doi: 10.1016/j.critrevonc.2016.11.015. Epub 2016 Nov 25. PMID: 28010896.

54. D'Argenio V, Torino M, Precone V, Casaburi G, Esposito MV, Iaffaldano L, **Malapelle U**, Troncone G, Coto I, Cavalcanti P, De Rosa G, Salvatore F, Sacchetti L. The Cause of Death of a Child in the 18th Century Solved by Bone Microbiome Typing Using Laser Microdissection and Next Generation Sequencing. *Int J Mol Sci*. 2017 Jan 6;18(1):109. doi: 10.3390/ijms18010109. PMID: 28067829; PMCID: PMC5297743.

55. **Malapelle U**, Sirera R, Jantus-Lewintre E, Reclusa P, Calabuig-Fariñas S, Blasco A, Pisapia P, Rolfo C, Camps C. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. *Expert Rev Mol Diagn*. 2017 Mar;17(3):209-215. doi: 10.1080/14737159.2017.1288568. Epub 2017 Feb 9. Erratum in: *Expert Rev Mol Diagn*. 2017 Mar;17 (3):i. PMID: 28129709.

56. **Malapelle U**, Maggio de-Las-Casas C, Rocco D, Garzon M, Pisapia P, Jordana-Ariza N, Russo M, Sgariglia R, De Luca C, Pepe F, Martinez-Bueno A, Morales-Espinosa D, González-Cao M, Karachaliou N, Viteri Ramirez S, Bellevicine C, Molina-Vila MA, Rosell R, Troncone G. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. *Br J Cancer*. 2017 Mar 14;116(6):802-810. doi: 10.1038/bjc.2017.8. Epub 2017 Feb 7. PMID: 28170370; PMCID: PMC5355934.

57. Forzati F, De Martino M, Esposito F, Sepe R, Pellecchia S, **Malapelle U**, Pellino G, Arra C, Fusco A. miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. *BMC Cancer*. 2017 Mar 4;17(1):170. doi: 10.1186/s12885-017-3158-z. PMID: 28259135; PMCID: PMC5336640.
58. De Luca C, Vigliar E, d'Anna M, Pisapia P, Bellevicine C, **Malapelle U**, Troncone G. KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test. *Cytojournal*. 2017 Feb 24;14:5. doi: 10.4103/1742-6413.200936. PMID: 28331530; PMCID: PMC5348988.
59. Clery E, Pisapia P, Feliciano S, Vigliar E, Marano A, De Luca C, **Malapelle U**, Troncone G, Bellevicine C. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression. *J Clin Pathol*. 2017 Sep;70(9):798-802. doi: 10.1136/jclinpath-2017-204370. Epub 2017 Mar 31. PMID: 28363898.
60. Sgariglia R, Pisapia P, Nacchio M, De Luca C, Pepe F, Russo M, Bellevicine C, Troncone G, **Malapelle U**. Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. *J Clin Pathol*. 2017 Sep;70(9):803-806. doi: 10.1136/jclinpath-2017-204373. Epub 2017 Apr 6. PMID: 28385922.
61. Della Corte CM, **Malapelle U**, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. *Oncotarget*. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479. PMID: 28416737; PMCID: PMC5410282.
62. **Malapelle U**, Maggiao-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borgh S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. *Cancer Cytopathol*. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 Maggio 5. PMID: 28475299.
63. **Malapelle U**, Pallante P. Editorial: Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs. *Front Med (Lausanne)*. 2017 Maggio 22;4:63. doi: 10.3389/fmed.2017.00063. PMID: 28589123; PMCID: PMC5439169.

64. De Stefano A, Rosanova M, **Malapelle U**, Martini M, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C. Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? *Int J Biol Markers*. 2017 Oct 31;32(4):e474-e477. doi: 10.5301/ijbm.5000273. PMID: 28665451.
65. Bellevicine C, **Malapelle U**, Vigliar E, Pisapia P, Vita G, Troncone G. How to prepare cytological samples for molecular testing. *J Clin Pathol*. 2017 Oct;70(10):819-826. doi: 10.1136/jclinpath-2017-204561. Epub 2017 Jul 24. PMID: 28739858.
66. Pisapia P, Lozano MD, Vigliar E, Bellevicine C, Pepe F, **Malapelle U**, Troncone G. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. *Cancer Cytopathol*. 2017 Nov;125(11):817-830. doi: 10.1002/cncy.21899. Epub 2017 Jul 25. PMID: 28743163.
67. Maggio-de-Las-Casas C, Garzón Ibáñez M, Jordana-Ariza N, García-Peláez B, Balada-Bel A, Villatoro S, **Malapelle U**, Karachaliou N, Troncone G, Rosell R, Molina-Vila MA. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. *Expert Rev Mol Diagn*. 2018 Jan;18(1):35-45. doi: 10.1080/14737159.2018.1407243. Epub 2017 Nov 26. PMID: 29172773.
68. Pisapia P, Pepe F, Smeraglio R, Russo M, Rocco D, Sgariglia R, Nacchio M, De Luca C, Vigliar E, Bellevicine C, Troncone G, **Malapelle U**. Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. *J Thorac Dis*. 2017 Oct;9(Suppl 13):S1383-S1390. doi: 10.21037/jtd.2017.06.97. PMID: 29184677; PMCID: PMC5676109.
69. Bellevicine C, Sgariglia R, Migliatino I, Vigliar E, D'Anna M, Nacchio MA, Serra N, **Malapelle U**, Bongiovanni M, Troncone G. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPAR γ alterations. *Cancer Cytopathol*. 2018 Maggio;126(5):317-325. doi: 10.1002/cncy.21984. Epub 2018 Feb 22. PMID: 29469940.
70. Bianco A, **Malapelle U**, Rocco D, Perrotta F, Mazzarella G. Targeting immune checkpoints in non small cell lung cancer. *Curr Opin Pharmacol*. 2018 Jun;40:46-50. doi: 10.1016/j.coph.2018.02.006. Epub 2018 Mar 9. PMID: 29525401.
71. Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, **Malapelle U**, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F. Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. *J Thorac Oncol*. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8. PMID: 29526823.

72. De Luca C, Rappa AG, Gragnano G, **Malapelle U**, Troncone G, Barberis M. Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm. *J Clin Pathol*. 2018 Aug;71(8):745-750. doi: 10.1136/jclinpath-2018-205197. Epub 2018 Maggio 24. PMID: 29798838.
73. Bruera G, Pepe F, **Malapelle U**, Pisapia P, Mas AD, Di Giacomo D, Calvisi G, Troncone G, Ricevuto E. KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. *Oncotarget*. 2018 Maggio 29;9(41):26279-26290. doi: 10.18632/oncotarget.25180. PMID: 29899858; PMCID: PMC5995185.
74. Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, **Malapelle U**, Qiu S, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. *Gastroenterol Res Pract*. 2018 Jun 13;2018:2397863. doi: 10.1155/2018/2397863. PMID: 30008744; PMCID: PMC6020538.
75. **Malapelle U**, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G. Osimertinib. *Recent Results Cancer Res*. 2018;211:257-276. doi: 10.1007/978-3-319-91442-8_18. PMID: 30069773.
76. Pepe F, De Luca C, Smeraglio R, Pisapia P, Sgariglia R, Nacchio M, Russo M, Serra N, Rocco D, Battiloro C, Ambrosio F, Gragnano G, Vigliar E, Bellevicine C, Troncone G, **Malapelle U**. Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. *J Clin Pathol*. 2019 Jan;72(1):38-45. doi: 10.1136/jclinpath-2018-205386. Epub 2018 Oct 2. PMID: 30279174.
77. Capo A, Sepe R, Pellino G, Milone M, **Malapelle U**, Pellecchia S, Pepe F, Cacciola NA, Manigrasso M, Bruzzaniti S, Sciaudone G, De Palma GD, Galgani M, Selvaggi F, Troncone G, Fusco A, D'Auria S, Pallante P. Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. *Nanomedicine*. 2019 Jan;15(1):231-242. doi: 10.1016/j.nano.2018.09.011. Epub 2018 Oct 9. PMID: 30308301.
78. Scimia M, Du J, Pepe F, Bianco MA, Russo Spena S, Patell-Socha F, Sun Q, Powell MJ, **Malapelle U***, Troncone G. Evaluation of a novel liquid biopsy-based ColoScope assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. *J Clin Pathol*. 2018 Dec;71(12):1123-1126. doi: 10.1136/jclinpath-2018-205412. Epub 2018 Oct 12. PMID: 30315134. (*corresponding author)
79. **Malapelle U**, Iaccarino A, Rossi A. Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for

immunotherapy. *Transl Lung Cancer Res.* 2018 Sep;7(Suppl 3):S221-S224. doi: 10.21037/tlcr.2018.08.09. PMID: 30393607; PMCID: PMC6193894.

80. Pisapia P, **Malapelle U**, Troncone G. Liquid Biopsy and Lung Cancer. *Acta Cytol.* 2019;63(6):489-496. doi: 10.1159/000492710. Epub 2018 Dec 19. PMID: 30566947.

81. Capalbo C, Belardinilli F, Raimondo D, Milanoetti E, **Malapelle U**, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marzoetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. *Cancers (Basel).* 2019 Jan 27;11(2):147. doi: 10.3390/cancers11020147. PMID: 30691222; PMCID: PMC6406354.

82. **Malapelle U**, Raez LE, Serrano MJ, Rolfo C; International Society of Liquid Biopsies (ISLB). Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial. *J Thorac Dis.* 2018 Dec;10(12):6388-6391. doi: 10.21037/jtd.2018.11.22. PMID: 30746171; PMCID: PMC6344757.

83. Pallante P, Pisapia P, Bellevicine C, **Malapelle U**, Troncone G. Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture. *Acta Cytol.* 2019;63(3):171-181. doi: 10.1159/000496213. Epub 2019 Feb 13. PMID: 30759433.

84. Pisapia P, Pepe F, **Malapelle U**, Troncone G. BRAF Mutations in Lung Cancer. *Acta Cytol.* 2019;63(3):247-250. doi: 10.1159/000496478. Epub 2019 Mar 6. PMID: 30840950.

85. Vigliar E, **Malapelle U**, Iaccarino A, Acanfora G, Pisapia P, Clery E, De Luca C, Bellevicine C, Troncone G. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. *J Clin Pathol.* 2019 Jun;72(6):412-417. doi: 10.1136/jclinpath-2019-205732. Epub 2019 Mar 7. PMID: 30846480.

86. Friedlaender A, Banna G, **Malapelle U**, Pisapia P, Addeo A. Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today? *Front Oncol.* 2019 Mar 19;9:166. doi: 10.3389/fonc.2019.00166. PMID: 30941314; PMCID: PMC6433884.

87. Clery E, Pisapia P, Vigliar E, **Malapelle U**, Bellevicine C, Troncone G, Schmitt FC. Role of Cytomorphology in the Era of Liquid Biopsy. *Acta Cytol.* 2019;63(6):497-505. doi: 10.1159/000499338. Epub 2019 Apr 3. PMID: 30943469.

88. Vigliar E, Pepe F, Migliat�o I, Nacchio M, Cesaro S, Della Pepa R, Bellevicine C, **Malapelle U**, Fassan M, Pane F, Picardi M, Troncone G. Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment. *Diagn Cytopathol.* 2019 Aug;47(8):749-757. doi: 10.1002/dc.24184. Epub 2019 Apr 5. PMID: 30953406.

89. Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, **Malapelle U**, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. *Clin Cancer Res*. 2019 Jul 1;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9. PMID: 30967421.
90. Pisapia P*, **Malapelle U***, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Maggio-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borcht S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. *Cancer Cytopathol*. 2019 Maggio;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25. PMID: 31021538. (*uguale contributo)
91. **Malapelle U**, Rossi A. Emerging angiogenesis inhibitors for non-small cell lung cancer. *Expert Opin Emerg Drugs*. 2019 Jun;24(2):71-81. doi: 10.1080/14728214.2019.1619696. Epub 2019 Maggio 22. PMID: 31092048.
92. De Luca C, Conticelli F, Leone A, Gragnano G, Salatiello M, Galasso P, Pisapia P, Grillo LR, Iaccarino A, Vigliar E, Bellevicine C, **Malapelle U**, Troncone G. Is the Idylla EGFR Mutation Assay feasible on archival stained cytological smears? A pilot study. *J Clin Pathol*. 2019 Sep;72(9):609-614. doi: 10.1136/jclinpath-2019-205863. Epub 2019 Maggio 20. PMID: 31110050.
93. Vigliar E, **Malapelle U**, Bono F, Fusco N, Cortinovis D, Valtorta E, Spyridon A, Bimbatti M, Zocchi M, Piva C, Gaudioso G, Iaccarino A, Morbini P, Pagni F. The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. *Biomed Res Int*. 2019 Apr 14;2019:6832909. doi: 10.1155/2019/6832909. PMID: 31111063; PMCID: PMC6487144.
94. Pisapia P, Bellevicine C, **Malapelle U**, De Luca C, Vigliar E, Troncone G. Bird's eye view of modern cytopathology: Report from the seventh international Molecular Cytopathology Meeting in Napoli, Italia, 2018. *Cancer Cytopathol*. 2019 Jun;127(6):350-357. doi: 10.1002/cncy.22118. Epub 2019 Maggio 28. PMID: 31135103.

95. Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, **Malapelle U***; Immune-Oncology YOUNG Group. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. *Biomed Res Int*. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. PMID: 31179334; PMCID: PMC6507101. (*corresponding author)
96. Bruera G, Massacese S, Pepe F, **Malapelle U**, Dal Mas A, Ciacco E, Calvisi G, Troncone G, Simmaco M, Ricevuto E. Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndRomas by pharmacogenomic biomarkers. *Ther Adv Med Oncol*. 2019 Maggio 10;11:1758835919846421. doi: 10.1177/1758835919846421. PMID: 31205502; PMCID: PMC6535746.
97. Banna GL, Olivier T, Rundo F, **Malapelle U**, Fraggetta F, Libra M, Addeo A. The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. *Front Med (Lausanne)*. 2019 Jul 31;6:172. doi: 10.3389/fmed.2019.00172. PMID: 31417906; PMCID: PMC6685050.
98. Covelli C, Parente P, Pepe F, Pisapia P, Fiordelisi F, **Malapelle U**. Mismatch repair proteins and microsatellite instability in solid pseudopapillary neoplasm of the pancreas. *Hepatobiliary Pancreat Dis Int*. 2019 Oct;18(5):491-492. doi: 10.1016/j.hbpd.2019.08.003. Epub 2019 Aug 22. PMID: 31477525.
99. **Malapelle U**, Rolfo C; International Society of Liquid Biopsy (ISLB). Liquid biopsy as a follow-up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors. *Cancer*. 2020 Jan 1;126(1):22-25. doi: 10.1002/cncr.32482. Epub 2019 Sep 10. PMID: 31503330.
100. Villatoro S, Maggiao-de-Las-Casas C, Jordana-Ariza N, Viteri-Ramírez S, Garzón-Ibañez M, Moya-Horno I, García-Peláez B, González-Cao M, **Malapelle U**, Balada-Bel A, Martínez-Bueno A, Campos R, Reguart N, Majem M, Blanco R, Blasco A, Catalán MJ, González X, Troncone G, Karachaliou N, Rosell R, Molina-Vila MA. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. *Mol Oncol*. 2019 Dec;13(12):2633-2645. doi: 10.1002/1878-0261.12574. Epub 2019 Oct 11. PMID: 31529604; PMCID: PMC6887582.
101. **Malapelle U***. USP11 role in colorectal cancer growing and metastatisation. *EBioMedicine*. 2019 Oct;48:5-6. doi: 10.1016/j.ebiom.2019.09.022. Epub 2019 Sep 17. PMID: 31537502; PMCID: PMC6838450. (*corresponding author)

102. Bianco A, Perrotta F, Barra G, **Malapelle U**, Rocco D, De Palma R. Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer. *Int J Mol Sci*. 2019 Oct 5;20(19):4931. doi: 10.3390/ijms20194931. PMID: 31590386; PMCID: PMC6801651.
103. Russo A, De Miguel Perez D, Gunasekaran M, Scilla K, Lapidus R, Cooper B, Mehra R, Adamo V, **Malapelle U**, Rolfo C. Liquid biopsy tracking of lung tumor evolutions over time. *Expert Rev Mol Diagn*. 2019 Dec;19(12):1099-1108. doi: 10.1080/14737159.2020.1680287. Epub 2019 Oct 16. PMID: 31608732.
104. **Malapelle U**, Rossi A, Bria E. Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing? *J Thorac Dis*. 2019 Sep;11(Suppl 15):S1837-S1840. doi: 10.21037/jtd.2019.08.99. PMID: 31632763; PMCID: PMC6783785.
105. Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M, Lopez G, Venetis K, Croci GA, **Malapelle U**, Fusco N. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. *Int J Mol Sci*. 2019 Nov 1;20(21):5452. doi: 10.3390/ijms20215452. PMID: 31683784; PMCID: PMC6862285.
106. Lettig L, Sahnane N, Pepe F, Cerutti R, Albeni C, Franzi F, Veronesi G, Ogliari F, Pastore A, Tuzi A, Pinotti G, Bovio A, Verusio C, Giordano M, Troncone G, Sessa F, **Malapelle U**, Furlan D. EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. *Transl Lung Cancer Res*. 2019 Oct;8(5):584-592. doi: 10.21037/tlcr.2019.09.18. PMID: 31737495; PMCID: PMC6835109.
107. Passiglia F, Calandri M, Guerrera F, **Malapelle U**, Mangone L, Ramella S, Trisolini R, Novello S. Lung Cancer in Italy. *J Thorac Oncol*. 2019 Dec;14(12):2046-2052. doi: 10.1016/j.jtho.2019.05.019. PMID: 31757374.
108. Bellevisine C, Migliatico I, Sgariglia R, Nacchio M, Vigliar E, Pisapia P, Iaccarino A, Bruzzese D, Fonderico F, Salvatore D, Biondi B, Masone S, Novizio V, Scavuzzo F, Serino D, De Palma M, Chiofalo MG, Botti G, Pezzullo L, Nuzzo V, Spiezia S, De Chiara G, Iorio S, Conzo G, Docimo G, Faggiano A, Bongiovanni M, **Malapelle U**, Colao A, Triassi M, Troncone G; Tiroide Network. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPAR γ alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. *Cancer Cytopathol*. 2020 Feb;128(2):107-118. doi: 10.1002/cncy.22217. Epub 2019 Dec 10. PMID: 31821746.
109. Pepe F, Pisapia P, Del Basso de Caro ML, Conticelli F, **Malapelle U**, Troncone G, Martinez JC. Next generation sequencing identifies novel potential actionable mutations for grade I

meningioma treatment. *Histol Histopathol.* 2020 Jul;35(7):741-749. doi: 10.14670/HH-18-195. Epub 2019 Dec 24. PMID: 31872418.

110. De Luca C, Sgariglia R, Nacchio M, Pisapia P, Migliatico I, Clery E, Gragnano G, Campione S, Vigliar E, **Malapelle U**, De Dominicis G, Bellevicine C, Troncone G. Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis. *Diagn Cytopathol.* 2020 Apr;48(4):300-307. doi: 10.1002/dc.24378. Epub 2020 Jan 6. PMID: 31904908.

111. Passiglia F, Pilotto S, Facchinetti F, Bertolaccini L, Del Re M, Ferrara R, Franchina T, **Malapelle U**, Menis J, Passaro A, Ramella S, Rossi G, Trisolini R, Novello S. Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. *Crit Rev Oncol Hematol.* 2020 Feb;146:102858. doi: 10.1016/j.critrevonc.2019.102858. Epub 2019 Dec 28. PMID: 31918343.

112. Rocco D, **Malapelle U**, Del Re M, Della Gravara L, Pepe F, Danesi R, Troncone G, Gridelli C. Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. *Expert Opin Drug Metab Toxicol.* 2020 Feb;16(2):87-96. doi: 10.1080/17425255.2020.1721460. Epub 2020 Jan 30. PMID: 31978315.

113. Bessi S, Pepe F, Ottavianantonio M, Pisapia P, **Malapelle U**, Troncone G, Biancalani M. Comparison between two different next generation sequencing platforms for clinical relevant gene mutation test in solid tumours. *J Clin Pathol.* 2020 Sep;73(9):602-604. doi: 10.1136/jclinpath-2019-206422. Epub 2020 Feb 14. PMID: 32060075.

114. Passiglia F, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, **Malapelle U**, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Novello S. Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. *Crit Rev Oncol Hematol.* 2020 Apr;148:102862. doi: 10.1016/j.critrevonc.2019.102862. Epub 2020 Jan 25. PMID: 32062311.

115. **Malapelle U**, Muscarella LA, Pisapia P, Rossi A. Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. *Expert Opin Investig Drugs.* 2020 Apr;29(4):363-372. doi: 10.1080/13543784.2020.1732922. Epub 2020 Feb 26. PMID: 32073317.

116. Gristina V*, **Malapelle U***, Galvano A, Pisapia P, Pepe F, Rolfo C, Tortorici S, Bazan V, Troncone G, Russo A. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. *Cancer Treat Rev.* 2020 Apr;85:101994. doi: 10.1016/j.ctrv.2020.101994. Epub 2020 Feb 21. PMID: 32113081. (*uguale contributo)

117. Pisapia P, Pepe F, Troncone G, **Malapelle U***. Predictive biomarkers for molecular pathology in lung cancer. *Biomark Med.* 2020 Mar;14(4):253-257. doi: 10.2217/bmm-2019-0490. Epub 2020 Mar 3. PMID: 32125183. (*corresponding author)
118. Passaro A, **Malapelle U**, Attili I, de Marinis F. Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between. *Cancer.* 2020 Jun 1;126(11):2594-2596. doi: 10.1002/cncr.32810. Epub 2020 Mar 10. PMID: 32154916.
119. **Malapelle U**, Pepe F, Pisapia P, Sgariglia R, Nacchio M, De Luca C, Lacalamita R, Tommasi S, Pinto R, Palomba G, Palmieri G, Vacirca D, Barberis M, Bottillo I, Grammatico P, Grillo LR, Costa V, Smeraglio R, Bruzzese D, Troncone G. Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel. *Front Oncol.* 2020 Mar 11;10:236. doi: 10.3389/fonc.2020.00236. PMID: 32219061; PMCID: PMC7078327.
120. Vigliar E, Iaccarino A, Bruzzese D, **Malapelle U**, Bellevicine C, Troncone G. Cytology in the time of coronavirus disease (covid-19): an Italian perspective. *J Clin Pathol.* 2020 Apr 20;jclinpath-2020-206614. doi: 10.1136/jclinpath-2020-206614. Epub ahead of print. PMID: 32312717; PMCID: PMC7211103.
121. Clery E, Pisapia P, Migliatico I, Pepe F, De Luca C, Russo M, De Rosa F, Smeraglia F, Insabato L, Vigliar E, **Malapelle U**, Mariconda M, Gridelli C, Troncone G. Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx. *Diagn Cytopathol.* 2020 Aug;48(8):759-764. doi: 10.1002/dc.24438. Epub 2020 Apr 22. PMID: 32320137.
122. Vigliar E, Iaccarino A, Campione S, Campanino MR, Clery E, Pisapia P, De Luca C, Bellevicine C, **Malapelle U**, De Dominicis G, Troncone G. PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation. *Diagn Cytopathol.* 2020 Jul;48(7):595-603. doi: 10.1002/dc.24439. Epub 2020 Apr 25. PMID: 32333728.
123. **Malapelle U**, Pepe F, Pisapia P, Loperto I, Scamardo MS, Egidio R, De Pascale T, De Vita A, Triassi M, Troncone G, Rubba F. La biopsia liquida quale segnale di progressione tumorale nel carcinoma polmonare: potenziale di intervento in prevenzione terziaria [Liquid biopsy as indication of tumour progression in lung cancer: a potential intervention in tertiary prevention]. *Epidemiol Prev.* 2020 Jan-Feb;44(1):84-88. Italian. doi: 10.19191/EP20.1.A002. PMID: 32374118.
124. Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, **Malapelle U**, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ; ISLB. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). *Crit Rev Oncol Hematol.* 2020 Jul;151:102978.

doi: 10.1016/j.critrevonc.2020.102978. Epub 2020 Maggio 5. Erratum in: Crit Rev Oncol Hematol. 2020 Aug 18;154:103058. PMID: 32428812.

125. **Malapelle U**, De Luca C, Iaccarino A, Pepe F, Pisapia P, Russo M, Sgariglia R, Nacchio M, Vigliar E, Bellevicine C, Schmitt FC, Troncone G. Predictive molecular pathology in the time of COVID-19. J Clin Pathol. 2020 Maggio 19;jclinpath-2020-206711. doi: 10.1136/jclinpath-2020-206711. Epub ahead of print. PMID: 32434770; PMCID: PMC7242869.

126. Belardinilli F, Capalbo C, **Malapelle U**, Pisapia P, Raimondo D, Milanoetti E, Yasaman M, Liccardi C, Paci P, Sibilio P, Pepe F, Bonfiglio C, Mezi S, Magri V, Coppa A, Nicolussi A, Gradilone A, Petroni M, Di Giulio S, Fabretti F, Infante P, Coni S, Canettieri G, Troncone G, Giannini G. Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Front Oncol. 2020 Maggio 7;10:560. doi: 10.3389/fonc.2020.00560. PMID: 32457828; PMCID: PMC7221020.

127. Frisone D, Friedlaender A, **Malapelle U**, Banna G, Addeo A. A BRAF new world. Crit Rev Oncol Hematol. 2020 Aug;152:103008. doi: 10.1016/j.critrevonc.2020.103008. Epub 2020 Maggio 26. PMID: 32485528.

128. Fusco N, Sajjadi E, Venetis K, Gaudio G, Lopez G, Corti C, Rocco EG, Criscitiello C, **Malapelle U**, Invernizzi M. PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? Genes (Basel). 2020 Jun 28;11(7):719. doi: 10.3390/genes11070719. PMID: 32605290; PMCID: PMC7397204.

129. Pagni F*, **Malapelle U***, Doglioni C, Fontanini G, Fraggetta F, Graziano P, Marzoetti A, Guerini Rocco E, Pisapia P, Vigliar EV, Buttitta F, Jaconi M, Fusco N, Barberis M, Troncone G. Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. Cancers (Basel). 2020 Jul 5;12(7):1800. doi: 10.3390/cancers12071800. PMID: 32635634; PMCID: PMC7408471. (*uguale contributo)

130. Nikiforova MN, Lepe M, Tolino LA, Miller ME, Ohori NP, Wald AI, Landau MS, Kaya C, **Malapelle U**, Bellevicine C, Troncone G, Nikiforov YE, Baloch Z. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer Cytopathol. 2020 Jul 22. doi: 10.1002/cncy.22331. Epub ahead of print. PMID: 32697051.

131. **Malapelle U**, Pisapia P, Iaccarino A, Barberis M, Bellevicine C, Brunnström H, de Biase D, De Maglio G, Ericson Lindquist K, Fassan M, Fontanini G, Gruppioni E, Hofman P, Merkelbach-Bruse S, Molina Vila MA, Pujals A, Rapa I, Righi L, Rosell R, Schildgen O, Schildgen V, Schmitt FC, Tallini G, Vander Borgh S, Vigliar E, Volante M, Wagener-Rydzek S, Weynand B, Troncone G. Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. J Clin

Pathol. 2020 Jul 31;jclinpath-2020-206957. doi: 10.1136/jclinpath-2020-206957. Epub ahead of print. PMID: 32737190; PMCID: PMC7397978.

132. Passiglia F*, **Malapelle U***, Del Re M, Righi L, Pagni F, Furlan D, Danesi R, Troncone G, Novello S. KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. Eur J Cancer. 2020 Sep;137:57-68. doi: 10.1016/j.ejca.2020.06.023. Epub 2020 Jul 31. PMID: 32745965. (*equal contribution)

133. Nacchio M, Sgariglia R, Gristina V, Pisapia P, Pepe F, De Luca C, Migliatino I, Clery E, Greco L, Vigliar E, Bellevicine C, Russo A, Troncone G, **Malapelle U**. KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. J Thorac Dis. 2020 Jul;12(7):3836-3843. doi: 10.21037/jtd.2020.01.19. PMID: 32802465; PMCID: PMC7399406.

134. Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, **Malapelle U**, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ; ISLB. Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (Luglio) (2020) 102978]. Crit Rev Oncol Hematol. 2020 Aug 18;154:103058. doi: 10.1016/j.critrevonc.2020.103058. Epub ahead of print. Erratum for: Crit Rev Oncol Hematol. 2020 Jul;151:102978. PMID: 32823147.

135. Vigliar E, Iaccarino A, Sciortino M, De Luca C, **Malapelle U**, Bellevicine C, Troncone G. Molecular predictive testing in precision oncology: The Italian experience. Cancer Cytopathol. 2020 Sep;128(9):622-628. doi: 10.1002/cncy.22290. PMID: 32885914.

136. **Malapelle U**, Parente P, Pepe F, De Luca C, Cerino P, Covelli C, Balestrieri M, Russo G, Bonfitto A, Pisapia P, Fiordelisi F, D'Armiento M, Bruzzese D, Loupakis F, Pietrantonio F, Triassi M, Fassan M, Troncone G, Graziano P. Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Cells. 2020 Sep 2;9(9):E2019. doi: 10.3390/cells9092019. PMID: 32887373.

137. **Malapelle U**, Vigliar E, Troncone G. Biomarkers predictive value in early stage non-small cell lung cancer. Transl Lung Cancer Res. 2020 Aug;9(4):956-959. doi: 10.21037/tlcr.2020.04.16. PMID: 32953474; PMCID: PMC7481621.

138. Reale ML, Bironzo P, Bertaglia V, Palesandro E, Leone G, Tabbò F, Bungaro M, Audisio M, Mariniello A, Rapetti SG, Di Stefano RF, Artusio E, Capelletto E, Sperone P, Boccuzzi A, Calandri M, Perboni A, **Malapelle U**, Passiglia F, Novello S. SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit. Front Oncol. 2020 Aug 19;10:1722. doi: 10.3389/fonc.2020.01722. PMID: 32974210; PMCID: PMC7466731.

139. Fumagalli C, Guerini-Rocco E, Buttitta F, Iapicca P, You W, Mauri M, Felicioni L, Troncone G, **Malapelle U**, Scarpa A, Zamboni G, Calistri D, Barberis M, Marzoetti A. Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. *J Clin Pathol*. 2020 Oct 5;jclinpath-2020-206800. doi: 10.1136/jclinpath-2020-206800. Epub ahead of print. PMID: 33020174.
140. Serrano MJ, Garrido-Navas MC, Diaz Mochon JJ, Cristofanilli M, Gil-Bazo I, Pauwels P, **Malapelle U**, Russo A, Lorente JA, Ruiz-Rodriguez AJ, Paz-Ares LG, Vilar E, Raez LE, Cardona AF, Rolfo C; International Society of Liquid Biopsy. Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. *Cancer Discov*. 2020 Nov;10(11):1635-1644. doi: 10.1158/2159-8290.CD-20-0466. Epub 2020 Oct 9. PMID: 33037026.
141. **Malapelle U**, Rossi G, Pisapia P, Barberis M, Buttitta F, Castiglione F, Cecere FL, Grimaldi AM, Iaccarino A, Marzoetti A, Massi D, Medicina D, Mele F, Minari R, Orlando E, Pagni F, Palmieri G, Righi L, Russo A, Tommasi S, Vermi W, Troncone G. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. *Crit Rev Oncol Hematol*. 2020 Oct 3;156:103118. doi: 10.1016/j.critrevonc.2020.103118. Epub ahead of print. PMID: 33038627.
142. Passaro A*, **Malapelle U***, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Understanding EGFR heterogeneity in lung cancer. *ESMO Open*. 2020 Oct;5(5):e000919. doi: 10.1136/esmoopen-2020-000919. PMID: 33067323; PMCID: PMC7569934. (*equal contribution)
143. Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali SZ, Baloch ZW, Bellevicine C, Bongiovanni M, Botsun P, Bruzzese D, Bubendorf L, Büttner R, Canberk S, Capitano A, Casadio C, Cazacu E, Cochand-Priollet B, D'Amuri A, Eloy C, Engels M, Fadda G, Fontanini G, Fulciniti F, Hofman P, Iaccarino A, Ieni A, Jiang XS, Kakudo K, Kern I, Kholova I, Liu C, Lobo A, Lozano MD, **Malapelle U**, Maleki Z, Michelow P, Musayev J, Özgün G, Oznur M, Peiró Marqués FM, Pisapia P, Poller D, Pyzlak M, Robinson B, Rossi ED, Roy-Chowdhuri S, Saieg M, Savic Prince S, Schmitt FC, Javier Seguí Iváñez F, Štoos-Veić T, Sulaieva O, Sweeney BJ, Tuccari G, van Velthuysen ML, VanderLaan PA, Vielh P, Viola P, Voorham R, Weynand B, Zeppa P, Faquin WC, Pitman MB, Troncone G. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. *Cancer Cytopathol*. 2020 Oct 27. doi: 10.1002/ency.22373. Epub ahead of print. PMID: 33108683.
144. Pisapia P, **Malapelle U**, Salatiello M, Rosell R, Troncone G. A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know. *Transl Lung Cancer Res*. 2020 Oct;9(5):2074-2081. doi: 10.21037/tlcr-20-795. PMID: 33209627; PMCID: PMC7653120.

145. de Biase D, Fassan M, **Malapelle U***. Next-Generation Sequencing in Tumor Diagnosis and Treatment. *Diagnostics (Basel)*. 2020 Nov 17;10(11):962. doi: 10.3390/diagnostics10110962. PMID: 33212911; PMCID: PMC7698429. (* corresponding author)
146. Pisapia P, Pepe F, Iaccarino A, Sgariglia R, Nacchio M, Russo G, Gragnano G, **Malapelle U**, Troncone G. BRAF: A Two-Faced Janus. *Cells*. 2020 Nov 27;9(12):E2549. doi: 10.3390/cells9122549. PMID: 33260892.
147. Iaccarino A, Pisapia P, Pepe F, Sgariglia R, Nacchio M, Russo G, Gragnano G, De Luca C, Troncone G, **Malapelle U**. Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study. *J Clin Pathol*. 2020 Dec 4;jclinpath-2020-207107. doi: 10.1136/jclinpath-2020-207107. Epub ahead of print. PMID: 33277344.
148. Palladino R, Migliatico I, Sgariglia R, Nacchio M, Iaccarino A, **Malapelle U**, Vigliar E, Salvatore D, Troncone G, Bellevicine C. Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic. *Endocrine*. 2020 Dec 7:1–6. doi: 10.1007/s12020-020-02559-z. Epub ahead of print. PMID: 33284396; PMCID: PMC7719849.
149. Sabbatino F, Liguori L, **Malapelle U**, Schiavi F, Tortora V, Conti V, Filippelli A, Tortora G, Ferrone CR, Pepe S. Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. *Front Oncol*. 2020 Nov 27;10:567289. doi: 10.3389/fonc.2020.567289. PMID: 33330039; PMCID: PMC7728995.
150. Pepe F, Pisapia P, Gristina V, Rocco D, Micheli M, Micheli P, Iaccarino A, Tufano R, Gragnano G, Russo G, De Luca C, Sgariglia R, Nacchio M, Girolami I, Eccher A, Russo A, Troncone G, **Malapelle U**. Tumor mutational burden on cytological samples: A pilot study. *Cancer Cytopathol*. 2020 Dec 30. doi: 10.1002/cncy.22400. Epub ahead of print. PMID: 33378102.
151. De Luca C, Pepe F, Iaccarino A, Pisapia P, Righi L, Listì A, Greco L, Gragnano G, Campione S, De Dominicis G, Pagni F, Sgariglia R, Nacchio M, Tufano R, Conticelli F, Vigliar E, Bellevicine C, Cortinovis DL, Novello S, Molina-Vila MA, Rosell R, Troncone G, **Malapelle U**. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. *Cancers (Basel)*. 2021 Jan 4;13(1):139. doi: 10.3390/cancers13010139. PMID: 33406752; PMCID: PMC7796105.
152. Vavala T, **Malapelle U**, Veggiani C, Ludovini V, Papotti M, Leone A, Graziano P, Minari R, Bono F, Sapino A, Manotti L, Troncone G, Pisapia P, Girlando S, Buffoni L, Righi L, Colantonio I, Bertetto O, Novello S. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker

screening in daily clinical practice. *J Clin Pathol*. 2021 Jan 28;jclinpath-2020-207339. doi: 10.1136/jclinpath-2020-207339. Epub ahead of print. PMID: 33509945.

153. **Malapelle U**, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. *Eur J Cancer*. 2021 Feb 12;146:74-83. doi: 10.1016/j.ejca.2021.01.015. Epub ahead of print. PMID: 33588147.

154. Vigliar E, Cepurnaite R, Iaccarino A, Pisapia P, De Luca C, **Malapelle U**, Bellevicine C, Troncone G. Cytopathology practice during the COVID-19 postlockdown: An Italian experience. *Cancer Cytopathol*. 2021 Feb 17. doi: 10.1002/cncy.22416. Epub ahead of print. PMID: 33595924.

155. Pisapia P, Pepe F, Iaccarino A, Sgariglia R, Nacchio M, Conticelli F, Salatiello M, Tufano R, Russo G, Gragnano G, Girolami I, Eccher A, **Malapelle U**, Troncone G. Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer. *Front Med (Lausanne)*. 2021 Feb 11;8:633923. doi: 10.3389/fmed.2021.633923. PMID: 33644101; PMCID: PMC7904874.

156. Gragnano G, Nacchio M, Sgariglia R, Conticelli F, Iaccarino A, De Luca C, Troncone G, **Malapelle U**. Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer. *J Clin Pathol*. 2021 Mar 1;jclinpath-2021-207416. doi: 10.1136/jclinpath-2021-207416. Epub ahead of print. PMID: 33649142.

157. Angerilli V, Galuppini F, Pagni F, Fusco N, **Malapelle U**, Fassan M. The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. *Diagnostics (Basel)*. 2021 Feb 18;11(2):339. doi: 10.3390/diagnostics11020339. PMID: 33670699; PMCID: PMC7922586.

158. Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, Öhrling K, Burdon P, **Malapelle U**, Büttner R. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. *Lung Cancer*. 2021 Feb 22;154:161-175. doi: 10.1016/j.lungcan.2021.02.026. Epub ahead of print. PMID: 33690091.

159. **Malapelle U**, Pilotto S, Passiglia F, Pepe F, Pisapia P, Righi L, Listì A, Bironzo P, Belluomini L, Tabbò F, Reale ML, Russo G, De Luca C, Novello S, Troncone G. Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. *Crit Rev Oncol Hematol*. 2021 Mar 17;160:103300. doi: 10.1016/j.critrevonc.2021.103300. Epub ahead of print. PMID: 33744362.

160. **Malapelle U**, Pepe F, Pisapia P, Sgariglia R, Nacchio M, Barberis M, Bilh M, Bubendorf L, Büttner R, Cabibi D, Castiglia M, De Andrea CE, de Biase D, Dumur CI, Fontanini G, Freire J, Gristina V, Hofman P, Ilie M, Lozano MD, Merkelbach-Bruse S, Pappesch R, Pelusi N, Roma G, Russo A, Savic S, Siemanowski J, Tallini G, Tischler V, Vander Borgh S, Weynand B, Xu T, Troncone G. TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. *J Clin Pathol*. 2021 Mar 25;jclinpath-2021-207450. doi: 10.1136/jclinpath-2021-207450. Epub ahead of print. PMID: 33766954.
161. Pisapia P, Costa JL, Pepe F, Russo G, Gragnano G, Russo A, Iaccarino A, de Miguel-Perez D, Serrano MJ, Denninghoff V, Quagliata L, Rolfo C, **Malapelle U***. Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021. *Crit Rev Oncol Hematol*. 2021 Mar 26:103311. doi: 10.1016/j.critrevonc.2021.103311. Epub ahead of print. PMID: 33781866.(*corresponding author).
162. Sgariglia R, Nacchio M, Migliatino I, Vigliar E, **Malapelle U**, Pisapia P, De Luca C, Iaccarino A, Salvatore D, Masone S, Troncone G, Bellevicine C. Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel. *J Clin Pathol*. 2021 Mar 31;jclinpath-2021-207429. doi: 10.1136/jclinpath-2021-207429. Epub ahead of print. PMID: 33789920.
163. Pisapia P, Pepe F, Sgariglia R, Nacchio M, Russo G, Conticelli F, Girolami I, Eccher A, Bellevicine C, Vigliar E, **Malapelle U**, Troncone G. Next generation sequencing in cytology. *Cytopathology*. 2021 Apr 1. doi: 10.1111/cyt.12974. Epub ahead of print. PMID: 33792981.
164. Addeo A, Passaro A, **Malapelle U**, Luigi Banna G, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. *Cancer Treat Rev*. 2021 Mar 19;96:102179. doi: 10.1016/j.ctrv.2021.102179. Epub ahead of print. PMID: 33798954.
165. Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, Prelaj A, Coco S, Longo L, Dal Bello MG, Alama A, Dellepiane C, Bennicelli E, **Malapelle U**, Genova C. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. *Int J Mol Sci*. 2021 Mar 5;22(5):2625. doi: 10.3390/ijms22052625. PMID: 33807876.
166. de Biase D*, **Malapelle U***, De Leo A, Maloberti T, Visani M, Pisapia P, Acquaviva G, Pepe F, Russo G, Iaccarino A, Pession A, Tallini G, Troncone G. Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations. *J Clin Pathol*. 2021 Apr 5;jclinpath-2021-207468. doi: 10.1136/jclinpath-2021-207468. Epub ahead of print. PMID: 33820865.(* uguale contributo e corresponding authors)
167. De Luca C, Gragnano G, Conticelli F, Cennamo M, Pisapia P, Terracciano D, **Malapelle U**, Montella E, Triassi M, Troncone G, Portella G. Evaluation of a fully closed real time PCR platform

for the detection of SARS-CoV-2 in nasopharyngeal swabs: a pilot study. *J Clin Pathol*. 2021 Apr 9;jclinpath-2021-207516. doi: 10.1136/jclinpath-2021-207516. Epub ahead of print. PMID: 33837109; PMCID: PMC8042579.

168. Fusco N*, **Malapelle U***, Fassan M, Marchiò C, Buglioni S, Zupo S, Criscitiello C, Vigneri P, Dei Tos AP, Maiorano E, Viale G. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Front Oncol*. 2021 Mar 25;11:644737. doi: 10.3389/fonc.2021.644737. PMID: 33842357; PMCID: PMC8027489.(*uguale contributo).

169. Denninghoff V, Russo A, de Miguel-Pérez D, **Malapelle U**, Benyounes A, Gittens A, Cardona AF, Rolfo C. Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective. *Cancers (Basel)*. 2021 Apr 6;13(7):1723. doi: 10.3390/cancers13071723. PMID: 33917282; PMCID: PMC8038650.

170. Galvano A, Gristina V, **Malapelle U**, Pisapia P, Pepe F, Barraco N, Castiglia M, Perez A, Rolfo C, Troncone G, Russo A, Bazan V. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. *ESMO Open*. 2021 Apr 30;6(3):100124. doi: 10.1016/j.esmoop.2021.100124. Epub ahead of print. PMID: 33940346.

171. Iaccarino A, Salatiello M, Migliatino I, De Luca C, Gragnano G, Russo M, Bellevicine C, **Malapelle U**, Troncone G, Vigliar E. PD-L1 and beyond: Immuno-oncology in cytopathology. *Cytopathology*. 2021 May 6. doi: 10.1111/cyt.12982. Epub ahead of print. PMID: 33955097.

172. **Malapelle U**, Leprieur EG, Kanga PT, Chiasseu MT, Rolfo C. Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy. *Front Oncol*. 2021 May 14;11:694578. doi: 10.3389/fonc.2021.694578. PMID: 34055656; PMCID: PMC8160459. (corresponding Author)

173. Russo A, Incorvaia L, Del Re M, **Malapelle U**, Capoluongo E, Gristina V, Castiglia M, Danesi R, Fassan M, Giuffrè G, Gori S, Marchetti A, Normanno N, Pinto C, Rossi G, Santini D, Sartore-Bianchi A, Silvestris N, Tagliaferri P, Troncone G, Cinieri S, Beretta GD. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. *ESMO Open*. 2021 Jun 3;6(3):100164. doi: 10.1016/j.esmoop.2021.100164. Epub ahead of print. PMID: 34091263.

174. **Malapelle U**, Buono M, Pisapia P, Russo G, Tufano R, Pepe F, Rolfo C, Troncone G. Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics. *Crit Rev*

Oncol Hematol. 2021 Jun 10;103394. doi: 10.1016/j.critrevonc.2021.103394. Epub ahead of print. PMID: 34119656.

175. Criscitiello C, Guerini-Rocco E, Viale G, Fumagalli C, Sajjadi E, Venetis K, Piciotti R, Invernizzi M, **Malapelle U**, Fusco N. Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. *Anticancer Agents Med Chem*. 2021 Jul 6. doi: 10.2174/1871520621666210706144112. Epub ahead of print. PMID: 34229592.

176. Passiglia F, Cinquini M, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, Larici AR, **Malapelle U**, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Novello S. Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. *J Clin Oncol*. 2021 Aug 10;39(23):2574-2585. doi: 10.1200/JCO.20.02574. Epub 2021 Jun 2. PMID: 34236916.

177. Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, **Malapelle U**, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. *J Thorac Oncol*. 2021 Jul 8:S1556-0864(21)02284-X. doi: 10.1016/j.jtho.2021.06.017. Epub ahead of print. PMID: 34246791.

178. Bruera G, Pepe F, **Malapelle U**, Di Staso M, Dal Mas A, Di Giacomo D, Scerbo G, Santilli M, Ciacco E, Simmaco M, Troncone G, Coco C, Giuliantè F, Ricevuto E. Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice. *Ann Transl Med*. 2021 Jun;9(12):1027. doi: 10.21037/atm-20-6636. PMID: 34277827; PMCID: PMC8267302.

179. Attili I, Del Re M, Guerini-Rocco E, Crucitta S, Pisapia P, Pepe F, Barberis M, Troncone G, Danesi R, de Marinis F, **Malapelle U**, Passaro A. The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. *Expert Rev Mol Diagn*. 2021 Aug;21(8):757-766. doi: 10.1080/14737159.2021.1943365. Epub 2021 Jul 18. PMID: 34278933.

180. Pallante P*, **Malapelle U***, Nacchio M, Sgariglia R, Galati D, Capitelli L, Zanotta S, Galgani M, Piemonte E, Sanduzzi Zamparelli A, Rea G, Bocchino M. Liquid Biopsy Is a Promising Tool for Genetic Testing in Idiopathic Pulmonary Fibrosis. *Diagnostics (Basel)*. 2021 Jul 2;11(7):1202. doi: 10.3390/diagnostics11071202. PMID: 34359285; PMCID: PMC8305941. (*uguale contributo).

181. Russo A, Incorvaia L, **Malapelle U**, Del Re M, Capoluongo E, Vincenzi B, Chiari R, Cortesi L, Danesi R, Florena AM, Fontanini G, Gori S, Marchetti A, Normanno N, Pinto C, Sangiolo D, Silvestris N, Tagliaferri P, Tallini G, Cinieri S, Beretta GD. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF

Italian Scientific Societies. Crit Rev Oncol Hematol. 2021 Aug 8;165:103436. doi: 10.1016/j.critrevonc.2021.103436. Epub ahead of print. PMID: 34371157.

182. Salati M, Venetis K, Fassan M, **Malapelle U**, Pagni F, Sajjadi E, Fusco N, Ghidini M. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. Future Oncol. 2021 Aug 18. doi: 10.2217/fon-2021-0228. Epub ahead of print. PMID: 34406032.

183. **Malapelle U***, Pepe F*, Pisapia P*, Altimari A, Bellevicine C, Brunnström H, Bruno R, Büttner R, Cirnes L, De Andrea CE, de Biase D, Dumur CI, Ericson Lindquist K, Fontanini G, Gautiero E, Gentien D, Hofman P, Hofman V, Iaccarino A, Lozano MD, Mayo-de-Las-Casas C, Merkelbach-Bruse S, Pagni F, Roman R, Schmitt FC, Siemanowski J, Roy-Chowdhuri S, Tallini G, Tresserra F, Vander Borgh S, Vielh P, Vigliar E, Vita GAC, Weynand B, Rosell R, Molina Vila MA, Troncone G. Reference standards for gene fusion molecular assays on cytological samples: an international validation study. J Clin Pathol. 2021 Aug 24;jclinpath-2021-207825. doi: 10.1136/jclinpath-2021-207825. Epub ahead of print. PMID: 34429353. (*uguale contributo).

184. Cortinovis D, **Malapelle U**, Pagni F, Russo A, Banna GL, Sala E, Rolfo C. Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. Transl Lung Cancer Res. 2021 Jul;10(7):3385-3400. doi: 10.21037/tlcr-20-1067. PMID: 34430374; PMCID: PMC8350105.

185. **Malapelle U**, Parente P, Pepe F, De Luca C, Pisapia P, Sgariglia R, Nacchio M, Gragnano G, Russo G, Conticelli F, Bellevicine C, Vigliar E, Iaccarino A, Covelli C, Balistreri M, Clemente C, Perrone G, Danza A, Scaramuzzi F, Fassan M, Troncone G, Graziano P. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Cells. 2021 Jul 24;10(8):1878. doi: 10.3390/cells10081878. PMID: 34440647; PMCID: PMC8391221.

186. Torres GF, Bonilla CE, Buitrago G, Arrieta O, **Malapelle U**, Rolfo C, Cardona AF. How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. Crit Rev Oncol Hematol. 2021 Aug 27;166:103459. doi: 10.1016/j.critrevonc.2021.103459. Epub ahead of print. PMID: 34461270.

187. Girolami I, Lucenteforte E, Eccher A, Marletta S, Brunelli M, Graziano P, Pisapia P, **Malapelle U**, Troncone G, Scarpa A, Huang T, Pantanowitz L. Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2021 Sep 3. doi: 10.1002/cncy.22509. Epub ahead of print. PMID: 34478240.

188. Pisapia P, Pepe F, Sgariglia R, Nacchio M, Russo G, Gragnano G, Conticelli F, Salatiello M, Luca C, Girolami I, Eccher A, Iaccarino A, Bellevicine C, Vigliar E, **Malapelle U**, Troncone G.

Methods for actionable gene fusion detection in lung cancer: now and in the future. *Pharmacogenomics*. 2021 Sep 16. doi: 10.2217/pgs-2021-0048. Epub ahead of print. PMID: 34525844.

189. Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, **Malapelle U**, Troncone G, Girolami I, Eccher A. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. *Pathol Res Pract*. 2021 Sep 1;226:153605. doi: 10.1016/j.prp.2021.153605. Epub ahead of print. PMID: 34530257.

190. Friedlaender A, Subbiah V, Russo A, Banna GL, **Malapelle U**, Rolfo C, Addeo A. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. *Nat Rev Clin Oncol*. 2021 Sep 24. doi: 10.1038/s41571-021-00558-1. Epub ahead of print. Erratum in: *Nat Rev Clin Oncol*. 2021 Oct 5;: PMID: 34561632.

191. **Malapelle U***, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, Cristofanilli M, De Miguel-Perez D, Denninghoff V, Durán I, Jantus-Lewintre E, Nuzzo PV, O'Byrne K, Pauwels P, Pickering EM, Raez LE, Russo A, Serrano MJ, Gandara DR, Troncone G, Rolfo C. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. *Expert Rev Mol Diagn*. 2021 Oct 11:1-14. doi: 10.1080/14737159.2021.1985468. Epub ahead of print. PMID: 34570988.(*corresponding author).

192. Friedlaender A, Subbiah V, Russo A, Banna GL, **Malapelle U**, Rolfo C, Addeo A. Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. *Nat Rev Clin Oncol*. 2022 Jan;19(1):70. doi: 10.1038/s41571-021-00571-4. Erratum for: *Nat Rev Clin Oncol*. 2022 Jan;19(1):51-69. PMID: 34611336.

193. **Malapelle U**, Pilotto S, Reale ML, Passiglia F, Pisapia P, Pepe F, Belluomini L, Galetta D, Cortinovis D, Tiseo M, Passaro A, Seminati D, Pagni F, Parra HS, Migliorino MR, Rocco D, Troncone G, Novello S. Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. *Crit Rev Oncol Hematol*. 2021 Nov 18;169:103536. doi: 10.1016/j.critrevonc.2021.103536. Epub ahead of print. PMID: 34801697.

194. Pisapia P, Pepe F, Baggi A, Barberis M, Galvano A, Gristina V, Mastrilli F, Novello S, Pagni F, Pasini S, Perrone G, Righi D, Russo A, Troncone G, **Malapelle U***. Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. *Crit Rev Oncol Hematol*. 2021 Nov 20;169:103525. doi: 10.1016/j.critrevonc.2021.103525. Epub ahead of print. PMID: 34813925. (*corresponding author).

195. Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, Vargas C, Otero J, Arrieta O, Zatarain-Barrón L, Sotelo C, Ordoñez C, García-Robledo JE, Rojas L, Bermúdez M,

- Gámez T, Mayorga D, Corrales L, Martín C, Recondo G, Mas L, Samtani S, Ricaurte L, **Malapelle U**, Russo A, Barrón F, Santoyo N, Rolfo C, Rosell R; ONCOLGroup; CLICaP. p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. *Transl Oncol*. 2022 Jan;15(1):101276. doi: 10.1016/j.tranon.2021.101276. Epub 2021 Nov 22. PMID: 34823093; PMCID: PMC8626684.
196. De Maglio G, Pasello G, Dono M, Fiorentino M, Follador A, Sciortino M, **Malapelle U***, Tiseo M*. The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. *Crit Rev Oncol Hematol*. 2021 Nov 29;169:103561. doi: 10.1016/j.critrevonc.2021.103561. Epub ahead of print. PMID: 34856311. (*uguale contributo).
197. Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Galvano A, Del Re M, **Malapelle U**, Chiari R, Conte P, Danesi R, Fassan M, Ferrara R, Genuardi M, Ghiorzo P, Gori S, Guadagni F, Marchetti A, Marchetti P, Midiri M, Normanno N, Passiglia F, Pinto C, Silvestris N, Tallini G, Vatrano S, Vincenzi B, Cinieri S, Beretta G. The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. *Crit Rev Oncol Hematol*. 2021 Dec 8;169:103567. doi: 10.1016/j.critrevonc.2021.103567. Epub ahead of print. PMID: 34896250.
198. Jacobs F, Cani M, **Malapelle U**, Novello S, Napoli VM, Bironzo P. Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients. *Cancers (Basel)*. 2021 Dec 16;13(24):6332. doi: 10.3390/cancers13246332. PMID: 34944952.
199. Pepe F, Pisapia P, Russo G, Nacchio M, Pallante P, Vigliar E, De Angelis C, Insabato L, Bellevicine C, De Placido S, Troncone G, **Malapelle U**. BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. *Genes (Basel)*. 2021 Nov 28;12(12):1917. doi: 10.3390/genes12121917. PMID: 34946865.
200. Kaen DL, Minatta N, Russo A, **Malapelle U**, de Miguel-Pérez D, Rolfo C. Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met? *Adv Exp Med Biol*. 2021;1342:113-142. doi: 10.1007/978-3-030-79308-1_4. PMID: 34972964.
201. Vigliar E, Pisapia P, Dello Iacovo F, Alcaraz-Mateos E, Ali G, Ali SZ, Baloch ZW, Bellevicine C, Bongiovanni M, Botsun P, Bruzzese D, Bubendorf L, Büttner R, Canberk S, Capitano A, Casadio C, Cazacu E, Cochand-Priollet B, D'Amuri A, Davis K, Eloy C, Engels M, Fadda G, Fontanini G, Fulciniti F, Hofman P, Iaccarino A, Ieni A, Jiang XS, Kakudo K, Kern I, Kholova I, Linton McDermott KM, Liu C, Lobo A, Lozano MD, **Malapelle U**, Maleki Z, Michelow P, Mikula MW, Musayev J, Özgün G, Oznur M, Peiró Marqués FM, Poller D, Pyzlak M, Robinson B, Rossi ED, Roy-Chowdhuri S, Saieg M, Savic Prince S, Schmitt FC, Seguí Iváñez FJ,

Štoos-Veić T, Sulaieva O, Sweeney BJ, Tuccari G, van Velthuysen ML, VanderLaan PA, Vielh P, Viola P, Voorham QJM, Weynand B, Zeppa P, Faquin WC, Pitman MB, Troncone G. COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study. *Cancer Cytopathol.* 2022 Jan 10. doi: 10.1002/cncy.22547. Epub ahead of print. PMID: 35006650.

202. Attili I, Passaro A, Pisapia P, **Malapelle U**, de Marinis F. Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. *Curr Oncol.* 2022 Jan 9;29(1):255-266. doi: 10.3390/currenol29010024. PMID: 35049698; PMCID: PMC8774526.

203. Parente P, **Malapelle U**, Angerilli V, Balistreri M, Lonardi S, Pucciarelli S, De Luca C, Pepe F, Russo G, Vigliar E, Danza A, Scaramuzzi F, Troncone G, Graziano P, Fassan M. MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice. *J Clin Pathol.* 2022 Feb 10;jclinpath-2022-208143. doi: 10.1136/jclinpath-2022-208143. Epub ahead of print. PMID: 35145019.

204. Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, Verde N, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, **Malapelle U**, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. *ESMO Open.* 2022 Apr;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. Epub 2022 Feb 3. Erratum in: *ESMO Open.* 2022 Apr 1;7(2):100471. PMID: 35219245; PMCID: PMC8810307.

205. Cantini L, Mentrasti G, Lo Russo G, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, La Verde N, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, **Malapelle U**, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli GP, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri MV, Emili R, Roca E, Migliore A, Galassi T, Rocchi MBL, Berardi R. Erratum to 'Evaluation of COVID-19 impact on DELAYing

diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]. ESMO Open. 2022 Apr;7(2):100471. doi: 10.1016/j.esmoop.2022.100471. Epub 2022 Apr 1. Erratum for: ESMO Open. 2022 Apr;7(2):100406. PMID: 35378403; PMCID: PMC8973259.

206. Comandatore A, Balsano R, Immordino B, Arguedas D, Capula M, Baglio SR, Garajová I, **Malapelle U**, Morelli L, Giovannetti E. "Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer. Crit Rev Oncol Hematol. 2022 May;173:103659. doi: 10.1016/j.critrevonc.2022.103659. Epub 2022 Apr 6. PMID: 35398264.

207. Nacchio M, Pisapia P, Pepe F, Russo G, Vigliar E, Porcelli T, Luongo C, Iaccarino A, Pagni F, Salvatore D, Troncone G, **Malapelle U**, Bellevicine C. Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. Expert Rev Endocrinol Metab. 2022 Mar;17(2):167-178. doi: 10.1080/17446651.2022.2060819. Epub 2022 Apr 11. PMID: 35404189.

208. Russo G, Pepe F, Pisapia P, Palumbo L, Nacchio M, Vigliar E, Pallante P, Parente P, Fassan M, Graziano P, Bellevicine C, Troncone G, **Malapelle U**, Iaccarino A. Microsatellite instability evaluation of patients with solid tumour: routine practice insight from a large series of Italian referral centre. J Clin Pathol. 2022 May 11;jclinpath-2022-208203. doi: 10.1136/jclinpath-2022-208203. Epub ahead of print. PMID: 35545354.

209. Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open. 2022 Jun;7(3):100459. doi: 10.1016/j.esmoop.2022.100459. Epub 2022 May 19. PMID: 35597177; PMCID: PMC9126927.

210. Cappello F, Angerilli V, Munari G, Ceccon C, Sabbadin M, Pagni F, Fusco N, **Malapelle U**, Fassan M. FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. J Pers Med. 2022 May 5;12(5):750. doi: 10.3390/jpm12050750. PMID: 35629172; PMCID: PMC9146170.

211. Bessi S, Pepe F, Russo G, Pisapia P, Ottaviantonio M, Biancalani F, Iaccarino A, Russo M, Biancalani M, Troncone G, **Malapelle U**. Comparison of two next-generation sequencing-based approaches for liquid biopsy analysis in patients with non-small cell lung cancer: a multicentre study. J Clin Pathol. 2022 Jun 14;jclinpath-2022-208308. doi: 10.1136/jclinpath-2022-208308. Epub ahead of print. PMID: 35701144.

212. Villani A, Potestio L, Fabbrocini G, Troncone G, **Malapelle U**, Scalvenzi M. The Treatment of Advanced Melanoma: Therapeutic Update. *Int J Mol Sci.* 2022 Jun 7;23(12):6388. doi: 10.3390/ijms23126388. PMID: 35742834; PMCID: PMC9223461.
213. Rojas L, Mayorga D, Ruiz-Patiño A, Rodríguez J, Cardona AF, Archila P, Avila J, Bravo M, Ricaurte L, Sotelo C, Arrieta O, Zatarain-Barrón ZL, Carranza H, Otero J, Vargas C, Barrón F, Corrales L, Martín C, Recondo G, Pino LE, Bermudez MA, Gamez T, Ordoñez-Reyes C, García-Robledo JE, de Lima VC, Freitas H, Santoyo N, **Malapelle U**, Russo A, Rolfo C, Rosell R; CLICaP. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors. *ESMO Open.* 2022 Aug;7(4):100500. doi: 10.1016/j.esmoop.2022.100500. Epub 2022 Jun 23. PMID: 35753086; PMCID: PMC9434139.
214. Cordeiro de Lima VC, Corassa M, Saldanha E, Freitas H, Arrieta O, Raez L, Samtani S, Ramos M, Rojas C, Burotto M, Chamorro DF, Recondo G, Ruiz-Patiño A, Más L, Zatarain-Barrón L, Mejía S, Nicolas Minata J, Martín C, Bautista Blaquier J, Motta Guerrero R, Aliaga-Macha C, Carracedo C, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Jaller E, Rodríguez J, Archila P, Bermudez M, Gamez T, Russo A, Viola L, **Malapelle U**, de Miguel Perez D, Rolfo C, Rosell R, Cardona AF. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). *Lung Cancer.* 2022 Aug;170:114-121. doi: 10.1016/j.lungcan.2022.06.010. Epub 2022 Jun 20. PMID: 35753125.
215. Cardona AF, Ruiz-Patiño A, Recondo G, Martín C, Raez L, Samtani S, Minata JN, Blaquier JB, Enrico D, Burotto M, Ordóñez-Reyes C, Chamorro DF, Garcia-Robledo JE, Corrales L, Zatarain-Barrón ZL, Más L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Rodríguez J, Archila P, Bermudez M, Gamez T, Cordeiro de Lima V, Freitas H, Russo A, Polo C, **Malapelle U**, Perez DM, Rolfo C, Viola L, Rosell R, Arrieta O. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP). *Clin Lung Cancer.* 2022 Sep;23(6):522-531. doi: 10.1016/j.clcc.2022.06.001. Epub 2022 Jun 6. PMID: 35798634.
216. Luca C, Pepe F, Pisapia P, Iaccarino A, Righi L, Listì A, Russo G, Campione S, Pagni F, Nacchio M, Conticelli F, Russo M, Fabozzi T, Vigliar E, Bellevicine C, Rocco D, Laudati S, Iannaci G, Daniele B, Gridelli C, Cortinovis DL, Novello S, Molina-Vila MA, Rosell R, Troncone G, **Malapelle U**. RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. *Per Med.* 2022 Sep;19(5):395-401. doi: 10.2217/pme-2022-0020. Epub 2022 Jul 8. PMID: 35801400.

217. Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, Pepe F, Bellevicine C, Russo A, La Civita E, Terracciano D, **Malapelle U**, Troncone G, Barone B. Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives. *Cancers (Basel)*. 2022 Jul 4;14(13):3272. doi: 10.3390/cancers14133272. PMID: 35805043; PMCID: PMC9265840.
218. Ceccon C, Angerilli V, Rasola C, Procaccio L, Sabbadin M, Bergamo F, **Malapelle U**, Lonardi S, Fassan M. Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. *Front Oncol*. 2022 Jun 28;12:930108. doi: 10.3389/fonc.2022.930108. PMID: 35837109; PMCID: PMC9273960.
219. Bellevicine C, Ciarrocchi A, Friedlaender A, **Malapelle U**, de Biase D. Editorial: Molecular Characterization of Thyroid Lesions in the Era of "Next-Generation" Techniques. *Front Endocrinol (Lausanne)*. 2022 Jun 29;13:955185. doi: 10.3389/fendo.2022.955185. PMID: 35846329; PMCID: PMC9278310.
220. Libera L, Sahnane N, Pepe F, Pisapia P, De Luca C, Russo G, Parente P, Covelli C, Chiaravalli AM, Sessa F, **Malapelle U**, Furlan D. Critical aspects of microsatellite instability testing in endometrial cancer: a comparison study. *Hum Pathol*. 2022 Oct;128:134-140. doi: 10.1016/j.humpath.2022.07.014. Epub 2022 Jul 21. PMID: 35872156.
221. Passiglia F, **Malapelle U**, Normanno N, Pinto C. Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC. *Cancer Treat Rev*. 2022 Sep;109:102438. doi: 10.1016/j.ctrv.2022.102438. Epub 2022 Jul 18. PMID: 35882108.
222. Pisapia P, L'Imperio V, Galuppini F, Sajjadi E, Russo A, Cerbelli B, Fraggetta F, d'Amati G, Troncone G, Fassan M, Fusco N, Pagni F, **Malapelle U**. The evolving landscape of anatomic pathology. *Crit Rev Oncol Hematol*. 2022 Oct;178:103776. doi: 10.1016/j.critrevonc.2022.103776. Epub 2022 Aug 5. PMID: 35934262.
223. Bakalis E, Ferraro A, Gavriil V, Pepe F, Kollia Z, Cefalas AC, **Malapelle U**, Sarantopoulou E, Troncone G, Zerbetto F. Universal Markers Unveil Metastatic Cancerous Cross-Sections at Nanoscale. *Cancers (Basel)*. 2022 Jul 31;14(15):3728. doi: 10.3390/cancers14153728. PMID: 35954392; PMCID: PMC9367376.
224. Pisapia P, Iaccarino A, De Luca C, Acanfora G, Bellevicine C, Bianco R, Daniele B, Ciampi L, De Felice M, Fabozzi T, Formisano L, Giordano P, Gridelli C, Ianniello GP, Libroia A, Maione P, Nacchio M, Pagni F, Palmieri G, Pepe F, Russo G, Salatiello M, Santaniello A, Scamarcio R, Seminati D, Troia M, Troncone G, Vigliar E, **Malapelle U**. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. *Int J Mol Sci*. 2022 Aug 1;23(15):8541. doi: 10.3390/ijms23158541. PMID: 35955681; PMCID: PMC9369105.

225. **Malapelle U**, Passiglia F. A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib. *EBioMedicine*. 2022 Sep;83:104213. doi: 10.1016/j.ebiom.2022.104213. Epub 2022 Aug 9. PMID: 35961202; PMCID: PMC9382231.
226. Rolfo C, **Malapelle U**, Russo A. Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients. *Cancer Res*. 2022 Aug 16;82(16):2826-2828. doi: 10.1158/0008-5472.CAN-22-2109. PMID: 35971678.
227. **Malapelle U**, Pisapia P, Pepe F, Russo G, Buono M, Russo A, Gomez J, Khorshid O, Mack PC, Rolfo C, Troncone G. The evolving role of liquid biopsy in lung cancer. *Lung Cancer*. 2022 Oct;172:53-64. doi: 10.1016/j.lungcan.2022.08.004. Epub 2022 Aug 10. PMID: 35998482.
228. **Malapelle U**, Fassan M, de Biase D. Special Issue: Next-Generation Sequencing in Tumor Diagnosis and Treatment II. *Diagnostics (Basel)*. 2022 Aug 20;12(8):2017. doi: 10.3390/diagnostics12082017. PMID: 36010367; PMCID: PMC9407571.
229. Horgan D, Čufer T, Gatto F, Lugowska I, Verbanac D, Carvalho Â, Lal JA, Kozaric M, Toomey S, Ivanov HY, Longshore J, **Malapelle U**, Hasenleithner S, Hofman P, Alix-Panabières C. Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring. *Healthcare (Basel)*. 2022 Sep 7;10(9):1714. doi: 10.3390/healthcare10091714. PMID: 36141326; PMCID: PMC9498805.
230. Krebs MG, **Malapelle U**, André F, Paz-Ares L, Schuler M, Thomas DM, Vainer G, Yoshino T, Rolfo C. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. *JAMA Oncol*. 2022 Dec 1;8(12):1830-1839. doi: 10.1001/jamaoncol.2022.4457. PMID: 36264554.
231. Venetis K, Pepe F, Munzone E, Sajjadi E, Russo G, Pisapia P, Ivanova M, Bonizzi G, Vacirca D, Rappa A, Ranghiero A, Taormina SV, Viale G, Troncone G, Barberis M, Guerini-Rocco E, **Malapelle U**, Fusco N. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2- Breast Cancer. *Cells*. 2022 Nov 9;11(22):3545. doi: 10.3390/cells11223545. PMID: 36428975; PMCID: PMC9688837.
232. **Malapelle U**, Orsulic S. Editorial: Molecular pathology and computational image analyses in gynecologic malignancies. *Front Oncol*. 2022 Nov 21;12:1082220. doi: 10.3389/fonc.2022.1082220. PMID: 36479087; PMCID: PMC9720375.
233. **Malapelle U**, Parente P, Pepe F, Di Micco MC, Russo A, Clemente C, Graziano P, Rossi A. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? *Int J Mol Sci*. 2022 Dec 16;23(24):16077. doi: 10.3390/ijms232416077. PMID: 36555714; PMCID: PMC9788608.

234. **Malapelle U**, Veronesi G. Editorial: Long non-coding RNAs in lung cancer. *Front Oncol.* 2022 Dec 12;12:1100061. doi: 10.3389/fonc.2022.1100061. PMID: 36578925; PMCID: PMC9791817.
235. Corte CMD, **Malapelle U**, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F. Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. *Oncotarget.* 2022 Dec 29;13:1369. doi: 10.18632/oncotarget.28335. Erratum for: *Oncotarget.* 8:23020. PMID: 36580516; PMCID: PMC9799319.
236. Serrano MJ, **Malapelle U**. Comments on roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation. *J Immunother Cancer.* 2023 Jan;11(1):e006106. doi: 10.1136/jitc-2022-006106. PMID: 36657814; PMCID: PMC9853213.
237. Iaccarino A, Nacchio M, Acanfora G, Pisapia P, **Malapelle U**, Bellevicine C, Troncone G, Vigliar E. Multiple predictive biomarker testing in melanoma: Another challenge in identifying the optimal approach on cytological samples. *Cytopathology.* 2023 May;34(3):198-203. doi: 10.1111/cyt.13211. Epub 2023 Feb 8. PMID: 36658094.
238. Fusco N, **Malapelle U**, Criscitiello C. Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers. *Front Mol Biosci.* 2023 Jan 4;9:1117323. doi: 10.3389/fmolb.2022.1117323. PMID: 36660432; PMCID: PMC9845888.
239. Filippi AR, Agustoni F, Arcangeli S, Cortinovis D, Ferrari A, Cicognini D, Saddi J, Klersy C, Pedrazzoli P, **Malapelle U**, Grossi F. Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial. *Clin Lung Cancer.* 2023 May;24(3):e122-e125. doi: 10.1016/j.clcc.2022.12.015. Epub 2023 Jan 20. PMID: 36759266.
240. Gavriil V, Ferraro A, Cefalas AC, Kollia Z, Pepe F, **Malapelle U**, De Luca C, Troncone G, Sarantopoulou E. Nanoscale Prognosis of Colorectal Cancer Metastasis from AFM Image Processing of Histological Sections. *Cancers (Basel).* 2023 Feb 14;15(4):1220. doi: 10.3390/cancers15041220. PMID: 36831563; PMCID: PMC9953928.
241. Bironzo P, Pepe F, Russo G, Pisapia P, Gragnano G, Aquino G, Bessi S, Buglioni S, Bartoccini F, Ferrero G, Bresciani MA, Francia di Celle P, Sibona F, Giusti A, Movilia A, Farioli RM, Santoro A, Salemi D, Scarpino S, Galafate D, Tommasi S, Lacalamita R, Seminati D, Sajjadi E, Novello S, Pagni F, Troncone G, **Malapelle U**. An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard

Reference Samples. *Diagnostics* (Basel). 2023 Feb 8;13(4):629. doi: 10.3390/diagnostics13040629. PMID: 36832117; PMCID: PMC9955861.

242. Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, **Malapelle U**, Biffi S. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches. *J Pers Med*. 2023 Feb 2;13(2):284. doi: 10.3390/jpm13020284. PMID: 36836518; PMCID: PMC9968181.

243. Rolfo C, **Malapelle U**, Russo A. Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non-Small-Cell Lung Cancer. *JCO Precis Oncol*. 2023 Feb;7:e2200674. doi: 10.1200/PO.22.00674. PMID: 36848608.

244. **Malapelle U**, Borralho P, Wang L, Schmitt F. Editorial: Cancer diagnostics in solid tumors- from pathology to precision oncology. *Front Mol Biosci*. 2023 Feb 21;10:1150641. doi: 10.3389/fmolb.2023.1150641. PMID: 36895807; PMCID: PMC9990903.

245. Venetis K, Sajjadi E, Ivanova M, Andaloro S, Pessina S, Zanetti C, Ranghiero A, Citelli G, Rossi C, Lucioni M, **Malapelle U**, Pagni F, Barberis M, Guerini-Rocco E, Viale G, Fusco N. The molecular landscape of breast mucoepidermoid carcinoma. *Cancer Med*. 2023 May;12(9):10725-10737. doi: 10.1002/cam4.5754. Epub 2023 Mar 14. PMID: 36916425; PMCID: PMC10225218.

246. Angerilli V, Fornaro L, Pepe F, Rossi SM, Perrone G, **Malapelle U**, Fassan M. FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice. *Pathologica*. 2023 Apr;115(2):71-82. doi: 10.32074/1591-951X-859. Epub 2023 Apr 5. PMID: 37017301.

247. Chamorro DF, Cardona AF, Rodríguez J, Ruiz-Patiño A, Arrieta O, Moreno-Pérez DA, Rojas L, Zatarain-Barrón ZL, Ardila DV, Viola L, Recondo G, Blaquier JB, Martín C, Raez L, Samtani S, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Archila P, Bermudez M, Gamez T, Russo A, **Malapelle U**, de Miguel Perez D, de Lima VCC, Freitas H, Saldahna E, Rolfo C, Rosell R; CLICaP. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. *Target Oncol*. 2023 May;18(3):425-440. doi: 10.1007/s11523-023-00955-9. Epub 2023 Apr 5. PMID: 37017806; PMCID: PMC10192162.

248. Al-Obeidi E, Riess JW, **Malapelle U**, Rolfo C, Gandara DR. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer. *Hematol Oncol Clin North Am*. 2023 Jun;37(3):475-487. doi: 10.1016/j.hoc.2023.02.005. Epub 2023 Apr 4. PMID: 37024388.

249. Horgan D, Capoluongo E, Dube F, Trapani D, **Malapelle U**, Rovite V, Omar MI, Alix-Panabières C, Rutkowski P, Bayle A, Hackshaw A, Hofman P, Subbiah V. Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake

of personalized medicine. *Diagnosis (Berl)*. 2023 Apr 10. doi: 10.1515/dx-2023-0022. Epub ahead of print. PMID: 37036891.

250. Pepe F, Guerini-Rocco E, Fassan M, Fusco N, Vacirca D, Ranghiero A, Venetis K, Rappa A, Taormina SV, Russo G, Rebellato E, Munari G, Moreno-Manuel A, De Angelis C, Zamagni C, Valabrega G, **Malapelle U**, Troncone G, Barberis M, Iaccarino A. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study. *J Clin Pathol*. 2023 Apr 18;jcp-2023-208852. doi: 10.1136/jcp-2023-208852. Epub ahead of print. PMID: 37072171.

251. Trisolini R, Bria E, Cetoretta V, Viscuso M, **Malapelle U**. Seize the Opportunity With Small Tissue Samples: The Tailor Teaches! *JTO Clin Res Rep*. 2023 Mar 24;4(4):100507. doi: 10.1016/j.jtocrr.2023.100507. PMID: 37101781; PMCID: PMC10123371.

252. Rolfo C, Russo A, **Malapelle U**. The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution? *EBioMedicine*. 2023 Jun;92:104605. doi: 10.1016/j.ebiom.2023.104605. Epub 2023 May 6. PMID: 37156171; PMCID: PMC10195843.

253. Rolfo C, Russo A, **Malapelle U**. The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution? *EBioMedicine*. 2023 Jun;92:104605. doi: 10.1016/j.ebiom.2023.104605. Epub 2023 May 6. PMID: 37156171; PMCID: PMC10195843.

254. **Malapelle U**, Angerilli V, Pepe F, Fontanini G, Lonardi S, Scartozzi M, Memeo L, Pruneri G, Marchetti A, Perrone G, Fassan M. The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective. *Pathologica*. 2023 Jun 14;115(3):137–47. doi: 10.32074/1591-951X-895. Epub ahead of print. PMID: 37314870; PMCID: PMC10462993.

255. Farinea G, Crespi V, Listì A, Righi L, Bironzo P, Merlini A, **Malapelle U**, Novello S, Scagliotti GV, Passiglia F. The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality. *J Thorac Oncol*. 2023 Sep;18(9):1146-1164. doi: 10.1016/j.jtho.2023.05.028. Epub 2023 Jun 16. PMID: 37331604.

256. Gosney JR, Paz-Ares L, Jänne P, Kerr KM, Leighl NB, Lozano MD, **Malapelle U**, Mok T, Sheffield BS, Tufman A, Wistuba II, Peters S. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. *ESMO Open*. 2023 Aug;8(4):101587. doi: 10.1016/j.esmoop.2023.101587. Epub 2023 Jun 23. PMID: 37356358; PMCID: PMC10485396.

257. **Malapelle U**, Tabbò F, Muscarella LA. Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC. *Front Oncol*. 2023 Jun 22;13:1239304. doi: 10.3389/fonc.2023.1239304. PMID: 37427122; PMCID: PMC10325716.

258. Gristina V, Pisapia P, Barraco N, Pepe F, Iacono F, La Mantia M, Peri M, Galvano A, Incorvaia L, Badalamenti G, Bazan V, Troncone G, Russo A, **Malapelle U**. The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? *Expert Rev Mol Diagn*. 2023 Jul-Dec;23(10):851-861. doi: 10.1080/14737159.2023.2245752. Epub 2023 Aug 8. PMID: 37552548.
259. Nacchio M, Palladino R, Vigliar E, Pisapia P, Salatiello M, **Malapelle U**, Porcelli T, Luongo C, Fonderico F, Masone S, Salvatore D, Troncone G, Bellevicine C. Evaluating local thyroid cytopathology practices by molecular quality metrics: A multi-institutional study on 4651 FNAs with a focus on the role of the interventional cytopathologist. *Cancer Cytopathol*. 2023 Dec;131(12):772-780. doi: 10.1002/cncy.22756. Epub 2023 Aug 28. PMID: 37635646.
260. Pisapia P, **Malapelle U**, Vielh P, Troncone G. The liquid biopsy series: A cytopathological perspective. *Cytopathology*. 2023 Nov;34(6):517-518. doi: 10.1111/cyt.13302. Epub 2023 Sep 7. PMID: 37675604.
261. Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, **Malapelle U**, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilić M. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. *ESMO Open*. 2023 Oct;8(5):101628. doi: 10.1016/j.esmoop.2023.101628. Epub 2023 Sep 14. PMID: 37713929; PMCID: PMC10594022.
262. Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, Mane E, Russo G, Taurelli Salimbeni B, Troncone G, Guerini Rocco E, Curigliano G, Fusco N, **Malapelle U**. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing. *Cancer Treat Rev*. 2023 Dec;121:102642. doi: 10.1016/j.ctrv.2023.102642. Epub 2023 Oct 13. PMID: 37864956.

263. **Malapelle U**, Uccella S, Cecere SC, De Angelis C, Giampaolino P. Editorial: Molecular predictive pathology in gynecologic malignancies. *Front Oncol*. 2023 Oct 4;13:1301768. doi: 10.3389/fonc.2023.1301768. PMID: 37869093; PMCID: PMC10586872.
264. Ferrara M, Pecorino B, D'Agate MG, Angelico G, Capoluongo ED, **Malapelle U**, Pepe F, Scollo P, Mereu L. Uterine Tumours Resembling Ovarian Sex-Cord Tumors: A Case Report and Review of the Literature. *J Clin Med*. 2023 Nov 16;12(22):7131. doi: 10.3390/jcm12227131. PMID: 38002745; PMCID: PMC10671931.
265. de Miguel-Perez D, Pickering EM, **Malapelle U**, Grier W, Pepe F, Pisapia P, Russo G, Pinto JA, Russo A, Troncone G, Culligan MJ, Scilla KA, Mehra R, Mohindra P, Arrieta O, Cardona AF, Del Re M, Sachdeva A, Hirsch FR, Wolf A, Friedberg JS, Rolfo C. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma. *Eur J Cancer*. 2024 Jan;196:113457. doi: 10.1016/j.ejca.2023.113457. Epub 2023 Nov 20. PMID: 38008032.
266. **Malapelle U**, Donne AD, Pagni F, Fraggetta F, Rocco EG, Pasello G, Perrone G, Pepe F, Vatrano S, Pignata S, Pinto C, Prunerì G, Russo A, Soto Parra HJ, Vallone S, Marchetti A, Troncone G, Novello S. Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group. *Crit Rev Oncol Hematol*. 2024 Jan;193:104217. doi: 10.1016/j.critrevonc.2023.104217. Epub 2023 Nov 30. PMID: 38040072.
267. Giunta EF, **Malapelle U**, Russo A, De Giorgi U. Blood-based liquid biopsy in advanced prostate cancer. *Crit Rev Oncol Hematol*. 2023 Dec 18;194:104241. doi: 10.1016/j.critrevonc.2023.104241. Epub ahead of print. PMID: 38122919.
268. Passiglia F, Lucia Reale M, Lo Russo G, Pasello G, Minuti G, Bulotta A, Galetta D, Pelizzari G, Sini C, Bria E, Roca E, Pilotto S, Genova C, Metro G, Citarella F, Chiari R, Cortinovis D, Delmonte A, Russo A, Tiseo M, Cerea G, Carta A, Scotti V, Vavalà T, Brambilla M, Buffoni L, Buosi R, Catania C, Gori S, Grisanti S, Agustoni F, Garbo E, **Malapelle U**, Novello S. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. *Lung Cancer*. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15. PMID: 38157806.
269. Gristina V, **Malapelle U**. Dissecting the nuances of cancer epigenomics in liquid biopsy. *Epigenomics*. 2024 Jan 3. doi: 10.2217/epi-2023-0326. Epub ahead of print. PMID: 38166432.
270. Casolino R, Beer PA, Chakravarty D, Davis MB, **Malapelle U**, Mazzarella L, Normanno N, Pauli C, Subbiah V, Turnbull C, Westphalen CB, Biankin AV. Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. *CA Cancer J Clin*. 2024 Jan 4. doi: 10.3322/caac.21825. Epub ahead of print. PMID: 38174605.

271. Marchiò C, Criscitiello C, Scatena C, Santinelli A, Graziano P, **Malapelle U**, Cursano G, Venetis K, Fanelli GN, Pepe F, Berrino E, Angelis C, Perrone G, Curigliano G, Fusco N. Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer. *Pathologica*. 2023 Dec;115(6):292-301. doi: 10.32074/1591-951X-942. PMID: 38180137; PMCID: PMC10767801.
272. Pepe F, Russo G, Venuta A, Scimone C, Nacchio M, Pisapia P, Goteri G, Barbisan F, Chiappetta C, Pernazza A, Campagna D, Giordano M, Perrone G, Sabarese G, Altimari A, de Biase D, Tallini G, Calistri D, Chiadini E, Capelli L, Santinelli A, Gulini AE, Pierpaoli E, Badiali M, Murru S, Murgia R, Guerini Rocco E, Venetis K, Fusco N, Morotti D, Gianatti A, Furlan D, Rossi G, Melocchi L, Russo M, De Luca C, Palumbo L, Simonelli S, Maffè A, Francia di Celle P, Venesio T, Scatolini M, Grosso E, Orecchia S, Fassan M, Balistreri M, Zulato E, Reghellin D, Lazzari E, Santacatterina M, Piredda ML, Riccardi M, Laurino L, Roz E, Longo D, Romeo DP, Fazzari C, Moreno-Manuel A, Puglia GD, Prjibelski AD, Shafranskaya D, Righi L, Listì A, Vitale D, Iaccarino A, **Malapelle U**, Troncone G. Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience. *Oncol Ther*. 2024 Jan 11. doi: 10.1007/s40487-023-00252-5. Epub ahead of print. PMID: 38200361.
273. Della Corte L, Russo G, Pepe F, Pisapia P, Dell'Aquila M, **Malapelle U**, Troncone G, Bifulco G, Giampaolino P. The role of liquid biopsy in epithelial ovarian cancer: state of the art. *Crit Rev Oncol Hematol*. 2024 Jan 11:104263. doi: 10.1016/j.critrevonc.2024.104263. Epub ahead of print. PMID: 38218208.
274. Horgan D, Van den Bulcke M, **Malapelle U**, Troncone G, Normanno N, Capoluongo ED, Prelaj A, Rizzari C, Trapani D, Singh J, Kozaric M, Longshore J, Ottaviano M, Boccia S, Pravettoni G, Cattaneo I, Malats N, Buettner R, Lekadir K, de Lorenzo F, Hofman P, De Maria R. Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems. *Heliyon*. 2023 Dec 20;10(1):e23914. doi: 10.1016/j.heliyon.2023.e23914. PMID: 38234913; PMCID: PMC10792189.
275. Horgan D, Bulcke MVD, **Malapelle U**, Normanno N, Capoluongo ED, Prelaj A, Rizzari C, Stathopoulou A, Singh J, Kozaric M, Dube F, Ottaviano M, Boccia S, Pravettoni G, Cattaneo I, Malats N, Buettner R, Lekadir K, de Lorenzo F, Blanc P, Alix-Panabieres C, Badreh S, Hofman P, Solary E, De Maria R. Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis. *Healthcare (Basel)*. 2024 Jan 19;12(2):259. doi: 10.3390/healthcare12020259. PMID: 38275541; PMCID: PMC10815829.
276. Pepe F, Venetis K, Cursano G, Frascarelli C, Pisapia P, Vacirca D, Scimone C, Rappa A, Russo G, Mane E, Pagni F, Castellano I, Troncone G, Angelis C, Curigliano G, Guerini-Rocco E, **Malapelle U**, Fusco N. PIK3CA testing in hormone receptor-positive/HER2-negative metastatic

breast cancer: real-world data from Italian molecular pathology laboratories. *Pharmacogenomics*. 2024 Feb;25(3):161-169. doi: 10.2217/pgs-2023-0238. Epub 2024 Mar 5. PMID: 38440825.

277. **Malapelle U**, Novello S. Biomarker testing in patients with advanced non-small cell lung cancer: the never-ending story. *Lancet Reg Health Eur*. 2024 Mar 1;38:100845. doi: 10.1016/j.lanepe.2024.100845. PMID: 38476750; PMCID: PMC10928263.

278. L'Imperio V, Cazzaniga G, Mannino M, Seminati D, Mascadri F, Ceku J, Casati G, Bono F, Eloy C, Rocco EG, Frascarelli C, Fassan M, **Malapelle U**, Pagni F. Digital counting of tissue cells for molecular analysis: the QuANTUM pipeline. *Virchows Arch*. 2024 Mar 26. doi: 10.1007/s00428-024-03794-9. Epub ahead of print. PMID: 38532196.

279. Spagnolo CC, Pepe F, Ciappina G, Nucera F, Ruggeri P, Squeri A, Speranza D, Silvestris N, **Malapelle U**, Santarpia M. Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path? *Crit Rev Oncol Hematol*. 2024 May;197:104332. doi: 10.1016/j.critrevonc.2024.104332. Epub 2024 Apr 4. PMID: 38580184.

280. **Malapelle U**, Passiglia F, Pepe F, Pisapia P, Lucia Reale M, Cortinovis D, Fraggetta F, Galetta D, Garbo E, Graziano P, Pagni F, Pasello G, Piovano P, Pilotto S, Tiseo M, Genova C, Righi L, Troncone G, Novello S. The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database. *Lung Cancer*. 2024 May;191:107787. doi: 10.1016/j.lungcan.2024.107787. Epub 2024 Apr 5. PMID: 38593479.

281. Barbato A, Piscopo F, Salati M, Pollastro C, Evangelista L, Ferrante L, Limongello D, Brillante S, Iuliano A, Reggiani-Bonetti L, Salatiello M, Iaccarino A, Pisapia P, **Malapelle U**, Troncone G, Indrieri A, Dominici M, Franco B, Carotenuto P. A MiR181/Sirtuin1 regulatory circuit modulates drug response in biliary cancers. *Clin Exp Med*. 2024 Apr 10;24(1):74. doi: 10.1007/s10238-024-01332-0. PMID: 38598008; PMCID: PMC11006774.

282. Seminati D, L'Imperio V, Casati G, Ceku J, Pilla D, Scalia CR, Gragnano G, Pepe F, Pisapia P, Sala L, Cortinovis DL, Bono F, **Malapelle U**, Troncone G, Novello S, Pagni F. Economic assessment of NGS testing workflow for NSCLC in a healthcare setting. *Heliyon*. 2024 Apr 5;10(7):e29272. doi: 10.1016/j.heliyon.2024.e29272. PMID: 38617925; PMCID: PMC11015456.

283. Scimia M, Pepe F, Russo G, Palumbo L, **Malapelle U**, Chuang R, Scimia S, Sha M, Tanaka H, Shen S, Chen D, Troncone G, Bianco MA. The Impact of potential 'confounders' on the diagnostic sensitivity of circulating free DNA in management of FIT+ patients: a pilot study. *J Clin Pathol*. 2024 Jul 18;77(8):557-560. doi: 10.1136/jcp-2024-209527. PMID: 38649261; PMCID: PMC11287558.

284. Horgan D, Van den Bulcke M, **Malapelle U**, Normanno N, Capoluongo ED, Prelaj A, Rizzari C, Stathopoulou A, Singh J, Kozaric M, Dube F, Ottaviano M, Boccia S, Pravettoni G, Cattaneo I,

Malats N, Buettner R, Lekadir K, de Lorenzo F, Alix-Panabieres C, Badreh S, Solary E, De Maria R, Hofman P. Demographic Analysis of Cancer Research Priorities and Treatment Correlations. *Curr Oncol*. 2024 Mar 29;31(4):1839-1864. doi: 10.3390/curroncol31040139. PMID: 38668042; PMCID: PMC11048756.

285. Eccher A, Seminati D, L'Imperio V, Casati G, Pilla D, **Malapelle U**, Piga I, Bindi G, Marando A, Bonoldi E, Dainese E, Riefolo M, D'Errico A, Costantini M, Lugli A, Grassi S, Scarpa A, Dei Tos AP, Pagni F. Pathology Laboratory Archives: Conservation Quality of Nucleic Acids and Proteins for NSCLC Molecular Testing. *J Pers Med*. 2024 Mar 22;14(4):333. doi: 10.3390/jpm14040333. PMID: 38672960; PMCID: PMC11050929.

286. Rossi G, Righi L, Barbisan F, Tiseo M, Spagnolo P, Grosso F, Pisapia P, **Malapelle U**, Sculco M, Dianzani I, Abate-Daga L, Davolio MC, Ceresoli GL, Galetta D, Pasello G, Novello S, Bironzo P. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report. *J Pers Med*. 2024 Apr 8;14(4):394. doi: 10.3390/jpm14040394. PMID: 38673021; PMCID: PMC11051266.

287. Pastò B, Buzzatti G, Schettino C, **Malapelle U**, Bergamini A, De Angelis C, Musacchio L, Dieci MV, Kuhn E, Lambertini M, Passarelli A, Toss A, Farolfi A, Roncato R, Capoluongo E, Vida R, Pignata S, Callari M, Baldassarre G, Bartoletti M, Gerratana L, Puglisi F. Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways. *Crit Rev Oncol Hematol*. 2024 Jul;199:104379. doi: 10.1016/j.critrevonc.2024.104379. Epub 2024 May 7. PMID: 38718940.

288. **Malapelle U**, Leighl N, Addeo A, HersHKovitz D, Hochmair MJ, Khorshid O, Länger F, de Marinis F, Peled N, Sheffield BS, Smit EF, Viteri S, Wolf J, Venturini F, O'Hara RM Jr, Rolfo C. Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer. *Br J Cancer*. 2024 Jul;131(2):212-219. doi: 10.1038/s41416-024-02709-4. Epub 2024 May 15. PMID: 38750115; PMCID: PMC11263606.

289. Guerini-Rocco E, Venetis K, Cursano G, Mane E, Frascarelli C, Pepe F, Negrelli M, Olmeda E, Vacirca D, Ranghiero A, Trapani D, Criscitiello C, Curigliano G, Rolfo C, **Malapelle U**, Fusco N. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2-metastatic breast cancer. *Crit Rev Oncol Hematol*. 2024 Sep;201:104427. doi: 10.1016/j.critrevonc.2024.104427. Epub 2024 Jun 23. PMID: 38917944.

290. Horgan D, Pesapane F, Van der Buckle M, de Maria R, Dube F, Singh J, Ługowska I, Bayle A, Hofman P, **Malapelle U**, Hills T, Capoluongo ED, Subbiah V. From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems. *Crit*

Rev Oncol Hematol. 2024 Sep;201:104433. doi: 10.1016/j.critrevonc.2024.104433. Epub 2024 Jun 30. PMID: 38955310.

291. Vigliar E, Carillo AM, Nacchio M, Cozzolino D, Acanfora G, Salatiello M, Pisapia P, **Malapelle U**, Troncone G, Bellevicine C. The evolving role of interventional cytopathology from thyroid FNA to NGS: Lessons learned at Federico II University of Naples. *Cytopathology*. 2024 Jul 9. doi: 10.1111/cyt.13415. Epub ahead of print. PMID: 38979838.

292. Sposito M, Belluomini L, Nocini R, Insolda J, Scaglione IM, Menis J, Simbolo M, Lugini A, Buzzacchino F, Verderame F, Spinnato F, Aprile G, Calveti L, Occhipinti M, Marinelli D, Veccia A, Lombardo F, Soto Parra HJ, Ferraù F, Savastano C, Porta C, Pradelli L, Sicari E, Castellani S, **Malapelle U**, Novello S, Bria E, Pilotto S, Milella M. Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study. *Front Oncol*. 2024 Jul 9;14:1436588. doi: 10.3389/fonc.2024.1436588. PMID: 39045557; PMCID: PMC11263796.

293. Scarpino S, Leone A, Galafate D, Pepe F, **Malapelle U**, Villani S, Giarnieri E, Maurizi G, De Vitis C, Mancini R, Mancini M, Di Napoli A, Vecchione A, Pillozzi E. Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study. *Int J Mol Sci*. 2024 Jul 11;25(14):7594. doi: 10.3390/ijms25147594. PMID: 39062837; PMCID: PMC11277451.

294. **Malapelle U**, Bellevicine C, Friedlaender A, Ciarrocchi A, de Biase D. Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume II. *Front Endocrinol (Lausanne)*. 2024 Jul 29;15:1460239. doi: 10.3389/fendo.2024.1460239. PMID: 39135622; PMCID: PMC11317369.

295. Reduzzi C, Nicolo' E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, Dipasquale A, Gouda MA, Saldanha EF, Kasi PM, Jantus-Lewintre E, Fusco N, **Malapelle U**, Gandara DR, Rolfo C, Serrano MJ, Cristofanilli M; International Society of Liquid Biopsy (ISLB). Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors. *Crit Rev Oncol Hematol*. 2024 Nov;203:104483. doi: 10.1016/j.critrevonc.2024.104483. Epub 2024 Aug 17. PMID: 39159706.

296. Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calveti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, **Malapelle U**, Novello S, Pasello G, Tiseo M. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database. *ESMO*

Open. 2024 Aug 29;9(9):103680. doi: 10.1016/j.esmoop.2024.103680. Epub ahead of print. PMID: 39214048; PMCID: PMC11402035.

297. Gristina V, Pepe F, Genova C, Bazan Russo TD, Gottardo A, Russo G, Incorvaia L, Galvano A, Badalamenti G, Bazan V, Troncone G, Russo A, **Malapelle U**. Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer. *Expert Rev Mol Diagn.* 2024 Sep 12:1-10. doi: 10.1080/14737159.2024.2403081. Epub ahead of print. PMID: 39267426.

298. Buonaiuto R, Neola G, Caltavitturo A, Longobardi A, Mangiacotti FP, Cefaliello A, Lamia MR, Pepe F, Ventriglia J, **Malapelle U**, Troncone G, Giuliano M, Arpino G, Pignata S, De Angelis C. Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type. *Front Oncol.* 2024 Sep 9;14:1412807. doi: 10.3389/fonc.2024.1412807. PMID: 39314634; PMCID: PMC11416912.

Capitoli di libro:

1. Pisapia P, **Malapelle U**, Troncone G. (2017). Clinical Practice Implications: Monitoring Drug Response and Resistance. *Liquid Biopsy in Cancer Patients*, pp 201-202, Springer.
2. Bellevicine C, **Malapelle U**, Vigliar E, Pisapia P, Ruosi C, Troncone G. (2018). How to Prepare Cytological Samples for Molecular Testing. *Molecular Applications in Cytology*, pp 11-28, Springer.
3. **Malapelle U**, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G. (2018). Osimertinib. *Small Molecules in Oncology*, Third Edition, pp 257-276. Springer.
4. **Malapelle U**, Pisapia P, Passiglia F, Dendooven A, Pauwels P, Salgado R, Rolfo C. (2019). Next-Generation Sequencing in Clinical Practice. *Oncogenomics*, pp 57-64. Academic Press.
5. **Malapelle U**, Pisapia P, Cieri M, Pepe F, Troncone G. (2019). RNA-Based Assays. *Molecular Diagnostics in Cytopathology*, pp 99-119. Springer, Cham.
6. Pisapia P, Cieri M, Pepe F, **Malapelle U**, Troncone G. (2019). DNA-Based Sequencing Assays. *Molecular Diagnostics in Cytopathology*, pp 83-97. Springer, Cham.

Partecipazione a congressi:

- 1: “Congresso Annuale di Anatomia Patologica SIAPEC-IAP”, 25-27 settembre 2008, Bari, Italia
- 2: “22nd European Congress of Pathology”, 04-09 settembre 2009, Firenze, Italia.

- 3: “Congresso Annuale di Anatomia Patologica SIAPEC-IAP”, 21-25 settembre 2010, Bologna, Italia.
- 4: “Molecular Cytopathology”, 04 Ottobre 2010, Napoli, Italia.
- 5: "Il ruolo della targeted therapy nelle neoplasie che iperesprimono EGFR", 14 Ottobre 2011, IRCCS-CROB, Rionero in Vulture, Italia.
- 6: "Congresso Annuale di Anatomia Patologica SIAPEC - IAP", 27-29 Ottobre 2011, Palermo, Italia.
- 7: "I Congresso nazionale di Citopatologia SIAPEC - IAP", 30 Giugno 2012, Trieste, Italia.
- 8: "III Molecular Cytopathology", 27 Settembre 2012, Napoli, Italia.
- 9: "GIST & TUMORI RARI", 28 Febbraio 2014, Napoli, Italia.
- 10: "IV Corso Nazionale AIOM - SIAPEC, Percorso e metodologia nella diagnostica molecolare in oncologia", 26 Marzo 2014, Roma, Italia.
- 11: "ESHO 2014 International Conference", 11-14 Giugno 2014, Torino, Italia.
- 12: “III Congresso Associazione Giovani Oncologi Campani - Update sul trattamento del tumore del colon e del retto”, 10 Ottobre 2014, Napoli, Italia.
- 13: “Congresso Annuale di Anatomia Patologica SIAPEC-IAP”, 22-25 Ottobre 2014, Firenze, Italia.
- 14: "Nuove evidenze nella gestione del carcinoma del colon metastatico", 17 Dicembre 2014, Pozzuoli, Italia.
- 15: "Principali evidenze e punti aperti nel trattamento di II linea dell'adenocarcinoma in stadio avanzato", 23 Gennaio 2015, Milano, Italia.
- 16: "Il confine tra benigno e maligno: il percorso diagnostico dalla morfologia alla biologia molecolare", 28-30 Gennaio 2015, Napoli, Italia.
- 17: "Il laboratorio di Patologia Molecolare: quale presente e quale futuro", 26-27 Febbraio 2015, Napoli, Italia.
- 18: "Metodologie di Anatomia Patologica per lo studio di Biomarcatori predittivi di risposta terapeutica", 9 Aprile 2015, Napoli, Italia.
- 19: "Strategie terapeutiche nel carcinoma del colon - retto metastatico", 28 Aprile 2015, Napoli, Italia.
- 20: "Primo incontro nazionale del gruppo di Patologia Molecolare e Medicina Predittiva (PMMP)", 20 Giugno 2015, Roma, Italia.
- 21: "Il patologo ed i test diagnostici di laboratorio: l'importanza della preclinica", 23 Giugno 2015, Napoli, Italia.
- 22: "Campus in Oncologia", 25-26 Giugno 2015, Bologna, Italia.

- 23: "Strategie terapeutiche in prima e seconda linea per i pazienti con NSCLC EGFR+ e EGFR WT", 11 Settembre 2015, Avellino, Italia.
- 24: "39th European Congress of Cytology", 20-23 Settembre 2015, Milano, Italia.
- 25: "Dalla Diagnosi morfologica alla biopsia liquida: la base per l'impostazione del percorso terapeutico", Congresso Nazionale AIOM, 23-25 Ottobre 2015, Roma, Italia.
- 26: "L'approccio terapeutico al paziente con NSCLC tra esperienze acquisite e prospettive future", 2 November 2015, Milano, Italia.
- 27: "Dalle evidenze del IASLC al dibattito aperto sulle attuali opzioni terapeutiche disponibili", 4 Novembre 2015, Aci Castello, Italia.
- 28: "Detectin Acquired Resistance on Liquid Biopsy", 10 Novembre 2015, Napoli, Italia.
- 29: "RAS master program", 11 Novembre 2015, Napoli, Italia.
- 30: "L'approccio terapeutico al paziente con NSCLC tra esperienze acquisite e prospettive future", 12 Novembre 2015, Roma, Italia.
- 31: "L'approccio terapeutico al paziente con NSCLC tra esperienze acquisite e prospettive future", 23 Novembre 2015, Napoli, Italia.
- 32: "Scientific Exchange meeting oncology on lung cancer", 1-2 Dicembre 2015, Milano, Italia.
- 33: "ALKUANTO: dall'importanza della determinazione di ALK all'importanza della gestione terapeutica appropriata", 18 Marzo 2016, Napoli, Italia.
- 34: "Marcatori Molecolari in Anatomia Patologica: quando, come e perchè", 8 Aprile 2016, University Maggiore della Carità, Novara, Italia.
- 35: "NSCLC: what has changed?", 6 Maggio 2016, Forte dei Marmi, Italia.
- 36: "La chemioterapia e le terapie target nell'era dell'immunoterapia", 20 Maggio 2016, Serravalle Scrivia, Italia.
- 37: "Terapie a bersaglio molecolare nel carcinoma del polmone. Monitoraggio molecolare: come, quando e perchè?", 26 Maggio 2016, Spedali Civili di Brescia, Brescia, Italia.
- 38: "II Incontro Nazionale del gruppo italiano di Patologia Molecolare e Medicina Predittiva", 31 Maggio 2016, Bologna, Italia.
- 39: "Privat meet. ASCO annual meeting 2016", 3-7 Giugno 2016, Chicago, IL, USA.
- 40: "Il carcinoma del colon-retto metastatico: strategie di trattamento attuali e future.", 22 Giugno 2016, Napoli, Italia.
- 41: "I congresso regionale FONICAP", 1 Luglio 2016, Cagliari, Italia.
- 42: "Next generation network: from the knowledge to know – how. focus on liquid biopsy", 29 Settembre 2016, Roma, Italia.

- 43: "Liquid biopsy in NSCLC clinical practice", 30 Settembre 2016, Università Piemonte Orientale, Novara, Italia.
- 44: "Private meet on NSCLC. ESMO 2016", 7-11 Ottobre 2016, Copenhagen, Danimarca.
- 45: "Microambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà", 11 Ottobre 2016, Milano, Italia.
- 46: "V Molecular Cytopathology", 18 Ottobre 2016, Napoli, Italia.
- 47: "FOCUS on Neoplasie e nuove terapie", 20 Ottobre 2016, Lucca, Italia.
- 48: "Strategie di trattamento nel NSCLC in stadio avanzato", 21 Ottobre 2016, Bologna, Italia.
- 49: "Oncologia molecolare del polmone - consenso informato e responsabilità professionale", 8 Novembre 2016, Napoli, Italia.
- 50: "Il carcinoma del colon retto metastatico: strategie di trattamento attuali e future", 9 Novembre 2016, Napoli, Italia.
- 51: "Nuove frontiere diagnostico terapeutiche nelle neoplasie polmonari, renali e nel melanoma", 12 Novembre 2016, Novara, Italia.
- 52: "Ulisse: finding the way in lung cancer", 22-23 Novembre 2016, Roma, Italia.
- 53: "Highlights in oncologia: il trattamento del carcinoma coloretale metastatico ras wild - type", 26 Novembre 2016, Rende, Italia.
- 54: "Ulisse: finding the way in lung cancer", 29 Novembre 2016, Napoli, Italia.
- 55: "Novità nei tumori polmonari", 30 Novembre 2016, Bolzano, Italia.
- 56: "PD-L1 un riferimento emergente nelle strategie dell'immunoncologia", 6 Dicembre 2016, Napoli, Italia.
- 57: "BEST OF WLCC 2016", Firenze, Italia, after "World Lung Cancer Conference 2016", 13 Dicembre 2016, Vienna, Austria.
- 58: "Le patologie emergenti, confronto interdisciplinare NSCLC EGFR+ VE: how the multidisciplinary approach wins the game", 16 Dicembre 2016, Monza, Italia.
- 59: "Master class mCRC2 2017", 7-8 Aprile 2017, Baveno, Italia.
- 60: "Stand Alone Scientific Symposium CTIO: Focus on Lung Cancer", 18-19 Aprile 2017, Roma, Italia.
- 61: "IO YOUNG: una nuova prospettiva per l'immunoterapia", 12-13 Maggio 2017, Milano, Italia.
- 62: "PD-L1: un riferimento emergente nell'immuno - oncologia", 15 Maggio 2017, Torino, Italia.

- 63: “Next Generation Technologies – simultaneous biomarkers evaluation in clinical practice”, 31 Maggio 2015, Napoli, Italia.
- 64: "III Incontro Nazionale del gruppo italiano di Patologia Molcolare e Medicina Predittiva", 6 Giugno 2017, Bologna, Italia.
- 65: “Congresso Nazionale dell’Associazione Italiana di Pneumologia Oncologica – AIPO – 2017”, 10-11 Giugno 2017, Firenze, Italia.
- 66: “La selezione del paziente NSCLC”, 16 Giugno 2017, Agrigento, Italia.
- 67: “Tavola rotonda sul trattamento del paziente con NSCLC.”, 22 Giugno 2017, Cagliari, Italia.
- 68: “Win symposium + meet the expert”, 25-27 Giugno 2017, Parigi, Francia.
- 69: “European Thoracic Oncology Platform”, 5-8 Ottobre 2017, Amsterdam, Olanda.
- 70: “Congresso Annuale di Anatomia Patologica SIAPEC-IAP”, 12-14 Ottobre 2017, Napoli, Italia.
- 71: “Congresso Nazionale della Associazione Italiana di Oncologia Medica – AIOM”, 27-29 Ottobre 2017, Roma, Italia.
- 72: “Next Generation Sequencing to Next Generation Oncologist”, 20 Novembre 2017, Istituto Mario Negri, Milano, Italia.
- 73: “VI Molecular Cytopathology”, 4 Dicembre 2017, Napoli, Italia.
- 74: "Next generation network: from the knoledge to know – how. focus on liquid biopsy”, 11 Dicembre 2017, Napoli, Italia.
- 75: “Oltre la 1^a linea: il percorso terapeutico del paziente con mRCC”, 19 Dicembre 2017, Napoli, Italia.
- 76: “IPF Connect 2.0”, 1 Febbraio 2018, Catania, Italia.
- 77: “IX Molecular Cytopathology”, 4 Dicembre 2020, Napoli, Italia.
- 78: Hot Topic Liquid Biopsy IASLC, Worldwide wirtual event, 2 -3 Ottobre 2020.
- 79: 16° CONGRESO URUGUAYO DE ONCOLOGIA, 18 Novembre 2020 (web – based), Montevideo, Uruguay.
- SOHC 2020, National Switzerland Congress of Oncology and Hematology, (we – based) Ginevra, Svizzera.
- European Congress of Pathology 2020, Thermo Fisher Scientific – Symposium, web based, 7 Dicembre 2020.
- Focus on uncommon EGFR mutations in NSCLC: for pathologists. 16 e 23 Marzo 2021.
- Track Member for Liquid Biopsy and other non invasive biomarkers and Discussant. WCLC 2021.

Premi:

2009: Best Cytopathology Study Award, 22nd European Congress of Pathology, Firenze, Italia.

2021: Frontiers in Oncology - GYN Associate Editorial Recognition Award.

Scopus

Numero di citazioni: 5672.

H-index: 43.

Google Scholar


Numero di citazioni: 7317.

H-index: 48.

Autorizzo il trattamento dei miei dati personali presenti nel cv ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 “Codice in materia di protezione dei dati personali” e del GDPR (Regolamento UE 2016/679).

30 maggio 2025

Umberto Malapelle

A handwritten signature in black ink, appearing to read 'Umberto Malapelle', is written over a faint, circular, textured background.